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ABSTRACT

Identifying mechanisms underlying the synergistic pathological interaction between
stroke and Alzheimer’s disease (AD) can effectively guide future therapeutic strategies
for these highly co-morbid conditions. Aberrant ganglioside expression marked by the
pathological accumulation of ganglioside GM3 is common to stroke and AD, yet it is
unclear whether GM3 is synergistically enhanced in a comorbid model, or if GM3 is a
viable therapeutic target. Adult male Wistar rats received a unilateral ischemic striatal
infarct via endothelin-1 (ET-1) injection alone or in combination with bilateral
intracerebroventricular injection of the β-Amyloid 25-35 peptide (Aβ) to induce
generalized Aβ toxicity (Aβ/ET-1). Animals were sacrificed after 3 or 21 days and
assessed via immunohistochemistry for neuroinflammation, neurodegeneration, and
ganglioside expression. Other animals were also treated with chloroquine (CQ)
systemically for seven days beginning 3 days before surgery as a novel therapeutic
approach to prevent the accumulation of GM3 by inhibiting degradation of complex
gangliosides. Our results showed that Aβ/ET-1 synergistically enhanced GM3
accumulation with concomitant reductions in complex gangliosides and neuronal survival
at 21 days. CQ reduced inflammation and GM3 accumulation at 21 days, and improved
neuronal survival. These findings suggest GM3 accumulation is a point of synergism
between stroke and Aβ toxicity, and CQ may be a viable therapeutic approach for stroke.
Key Words: Alzheimer’s Disease, Aβ, Stroke, Neuroinflammation, Gangliosides, GM3,
Chloroquine
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INTRODUCTION
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1.1 Alzheimer’s Disease
Alzheimer’s disease (AD) is synonymous with the elderly, yet in the context of the

human species it is a relatively young disease. First characterized just over a century ago,
AD is a devastating disease whose primary risk factor is age (Hardy and Allsop, 1991),
and thus represents a significant impending burden upon the industrialized nations of the
world with aging populations. AD is the most common (Querfurtth and LaFerla, 2010)
and most aggressive (Humpel, 2011) form of dementia, as well as one of the most
complex diseases of the central nervous system (CNS) as its pathogenesis is distinct from
the normal aging process, yet inextricably linked to it (Hardy and Allsop, 1991).
AD is a progressive disease resulting in severe synaptic loss, generalized cortical
atrophy and dementia (Katsman and Saitoh, 1991). There are some autosomal dominant
genetic mutations that are known to cause early-onset AD, or familial AD (FAD) (van
Duijn et al., 1991), however estimates are that these only represent 1-10% of patients, and
the vast majority of patients are classified as sporadic AD (Zlokovic, 2008; Yu et al.,
2010) because the cause is not known. In sporadic AD, the disease rarely manifests
clinically before the age of 65, and is generally believed to be the result of the
accumulation and deposition of β-amyloid (Aβ) over many decades which triggers a
pathological cascade marked by the accumulation of hyperphosphorylated tau, synapse
loss, neuronal death, and ultimately dementia (Hardy and Allsop, 1991; Hardy and
Higgins, 1992; Hardy and Selkoe, 2002).
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1.2 Aβ – The Hallmark of AD
AD is characterized by various neuropathological markers, including synaptic and
neuronal loss, intraneuronal neurofibrillary tangles and the distinctive presence of
amyloid plaques (Hardy and Higgins, 1991, 1992; Katsman and Saitoh, 1991; Nelson et
al., 2009). Diagnosis of AD is dependent on the presence of amyloid plaques (Herrup,
2010), which are comprised mainly of insoluble fibrils of Aβ peptides (Glenner and
Wong, 1984). Aβ is formed from amyloid precursor protein (APP) (Kang et al., 1987), a
transmembrane protein whose physiological function is poorly understood (Tsuruma et
al, 2010). Aβ is a 39-42 amino acid peptide (Lee et al., 1991) generated via the sequential
cleavage of APP by β- and γ-secretase (Haass et al., 1992; Steiner and Haass, 2000). Cterminal fragments of APP resulting from β-secretase cleavage can be cleaved at a variety
of sites within the transmembrane domain by γ-secretase, releasing a variety of Aβ
peptides that can spontaneously oligomerize into soluble aggregates, and eventually form
the insoluble fibrils found in amyloid plaques (Crowther, 1991; Hardy and Higgins,
1992). Amyloid plaques are resistant to proteolysis and are characteristically surrounded
by dystrophic neurites as well as reactive microglia and astrocytes (Hardy and Allsop,
1991).
The physiological function of APP is far from clear, as although it is associated
with the cytotoxic effects of Aβ (Kowall et al., 1991; Hardy and Higgins, 1992), APP
knock-out (KO) mice display metabolic abnormalities and behavioural deficits (Hiltunen
et al., 2009), specifically learning impairments and underlying synaptic defects (Ring et
al., 2007; Dawson et al., 1999). APP can undergo alternative non-amyloidogenic
processing by α- and γ-secretase, which precludes the formation of Aβ peptides (Tamboli
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et al., 2005): α-secretase cleaves APP within the Aβ domain (Tamboli et al., 2005)
producing p3 and soluble APPα (sAPPα), which is associated with neuroprotection
(Fahrenholz, 2007; Tsuruma et al., 2010).
A variety of factors can influence the expression of Aβ, such as intracellular
cholesterol levels which is believed to affect Aβ production indirectly via the
redistribution of APP and α/β secretases between distinct membrane microdomains
(Reviewed by Tamboli et al., 2005). The most significant genetic risk factor for
developing sporadic AD is the apo-lipoprotein E4 (ApoE4) allele, which is also
associated with susceptibility to hypercholesterolemia (Prasher et al., 2008). Lowering
cholesterol levels with statin therapy was shown to reduce the risk of developing AD in
observational studies, however there was conflicting data from subsequent clinical trials
(Jones et al., 2008; Sparks et al, 2005). Neuronal stressors (Abe et al., 1991), cytokines
(Goldgaber et al., 1989; Ge and Lahiri, 2002) and even Aβ can increase expression of
APP (Davis-Salinas et al. 1995; Schmitt et al. 1997), while Aβ deposition occurs
following acute neuronal injury in both humans and animals (Kawarabayashi et al.,
1991).
1.3 The Amyloid Cascade Hypothesis
The amyloid cascade hypothesis posits that the accumulation of Aβ is the primary
event that triggers the pathological cascade in all cases of AD, both sporadic and genetic
(Hardy and Allsop, 1991; Hardy and Higgins, 1992). Neuropathological events such as
synapse loss, neuroinflammation, formation of neurofibrillary tangles, altered neuronal
ionic homeostasis, oxidative stress and neuronal loss were originally believed to be a
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consequence of amyloid plaque concentrations reaching a certain threshold in the brain
(Hardy and Higgins, 1992; Iwata et al., 2005; Selkoe, 2001; Hardy & Selkoe, 2002;
Forman et al., 2004), however small soluble oligomers of amyloid are now thought to be
the initiating factor for AD (Tam and Pasternak, 2012; Benilova et al., 2012).
The strongest evidence that Aβ plays a causal role in AD is from the rare genetic
forms of FAD; mutations in APP or Presenilin (PSEN) – the catalytic subunit of the γsecretase complex responsible for liberating Aβ from APP – genes can result in the
accelerated accumulation of Aβ or the relative amount of Aβ42 to Aβ40, respectively,
and are sufficient to cause early-onset AD (Hardy and Allsop, 1991; Benilova et al.,
2012; Yu et al., 2010; Zlokovic, 2008). Since the APP gene is located on chromosome
21, individuals with Down’s syndrome harbor an extra copy of the APP gene and
invariably develop pathological signs indistinguishable from early-onset AD via gene
duplication (Hardy and Allsop, 1991). The sequential pathology in individuals with
Down’s syndrome further supports the causative role of Aβ in AD, as the accumulation
of Aβ is the first detectable pathological change (Rumble et al., 1989), followed much
later by neurofibrillary tangles and loss of neurons (Mann, Royston and Ravindra, 1990).
In sporadic cases of AD, Aβ accumulation is not a result of overproduction, but
due to age-related failures in Aβ clearance mechanisms (Reviewed by Zlokovic, 2008).
The amyloid cascade hypothesis is well established, if not accepted as fact, for genetic
cases of AD (Hardy and Selkoe, 2002). AD pathogenesis is not as well understood for
sporadic cases of AD, however it is believed that once the concentration of Aβ has
reached a certain threshold, the amyloid cascade is initiated and the disease follows the
same pathway to dementia as the genetic forms of AD (Hardy and Higgins, 1992; Herrup,
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2010) and is the rationale behind a non-transgenic animal model of AD established by
our lab (Whitehead et al., 2005a, b, 2007).
1.4 Autophagy in AD
One clearance mechanism that shows an age-related decline is autophagy, a
lysosomal-mediated pathway that serves to provide cells with metabolic substrates to
meet energy demands during nutrient deprivation or other stressful conditions, and a
primary defense mechanism for selectively clearing old and damaged organelles or large
intracellular protein aggregates, such as Aβ, from a cell (Seglen et al., 1996; Mortimore
and Schworer, 1977; Yu et al., 2005; Rami, 2009). Autophagy is especially important for
cells such as neurons and myocytes that do not divide after differentiating, as it represents
a cellular adaptation to stress (Rami, 2009). Over-activation of autophagy can lead to cell
death due to cellular atrophy (Nixon, 2007), while impaired autophagic function increases
neuronal vulnerability in AD (Cataldo et al., 1996; Herrup, 2010).
There is an age-associated decline in proteolytic activity causing a disruption in
lysosomal, and therefore autophagic, function (Yu et al., 2005). This leads to the
accumulation and enlargement of autophagic vacuoles (AVs) whose contents cannot be
degraded, and is identifiable early in sporadic AD and Down’s syndrome and precedes
extra-neuronal Aβ deposition and plaque formation (Cataldo et al., 2000; MolanderMelin et al., 2005). The acidification of lysosomes (pH 4.5) is required for efficient
autophagy, and is facilitated in part by by the presenilins (Lee et al., 2010). PSEN1
mutations not only promote the generation of toxic Aβ42 species, but have also been
shown to prevent lysosomal acidification (Lee et al., 2010), effectively impairing
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autophagy and the cell’s ability to clear Aβ aggregates and hyperphosphorylated tau,
resembling an adult-onset lysosomal storage disease (Tam & Pasternak, 2012).
1.5 From Aβ to AD
Despite the central role ascribed to Aβ in the pathogenesis of AD, the
accumulation of Aβ does not always precipitate the disease, as the presence of amyloid
plaques does not predict disease severity (Benilova et al., 2012). The abnormal
accumulation and deposition of Aβ occurs many years prior to the onset of cognitive
impairment (Benilova et al., 2012) and while the presence of Aβ is necessary for the
diagnosis of AD, approximately 40% of non-demented individuals met diagnostic criteria
for AD based strictly on Aβ plaque levels in the brain (Bennett et al., 2006, Price et al.,
2009). Transgenic mouse models of APP-overexpression show no neurodegeneration
despite Aβ plaque formation and neuroinflammation (Benilova et al., 2012; Abramowski
et al., 2012), and this discrepancy between neuronal loss and Aβ deposition in animal
models and the human disease is highly controversial.
In vitro studies found that among naturally occurring Aβ peptides, Aβ1-42 - which
is less prevalent in vivo than Aβ1-40 - demonstrated the greatest tendency to aggregate, as
well as the greatest toxicity towards cultured hippocampal neurons (Yankner et al., 1990;
Selkoe, 1998; Iwata et al., 2005; Querfurth and LaFerla, 2010). Amino acid substitutions
in the Aβ peptide sequence that enhanced aggregation of the peptide also enhanced the
neurotoxicity of the peptide in vitro (Pike et al., 1995). While the fibrillization of Aβ is
considered by some to be a key pathogenic process in AD (Yanagisawa et al., 2011),
soluble aggregates of Aβ are now the focus of the amyloid hypothesis of AD as they have
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shown greater neurotoxicity than the insoluble fibrils found in plaques (Kayed et al.,
2003; Glabe, 2008), and neuronal and synaptic loss has been shown to correlate with
levels of soluble Aβ in AD brains (Lue et al., 1999; Naslund et al., 2000). It is
intrinsically difficult to identify or accurately define which soluble species are
pathogenic, as Aβ peptides are a heterogeneous mixture of peptides of differing solubility
and stability (Benilova et al., 2012) that can aggregate into a variety of structures from
soluble dimers, trimers and oligomers, to the insoluble fibrils found in plaques (Selkoe,
2002; Walsh and Selkoe, 2007; Lacor et al., 2007; Lesne et al., 2006), all with different
biological and toxic properties. The synthetic Aβ25-35 fragment - termed the ‘active’
fragment (Yankner et al., 1990) - is a convenient tool to study Aβ toxicity as it can induce
similar toxicity mechanisms in vitro and in vivo as the full-length Aβ peptides (Yankner
et al., 1990; Pike et al., 1995; Tsuruma et al., 2010; El Khoury et al., 1996; Frozza et al.,
2009), is able to aggregate into soluble oligomers (Kowall et al., 1992), and has been
isolated from AD patients’ brains (Kubo et al., 2002).
1.6 Cerebral Amyloid Angiopathy
Aβ accumulation is not only damaging to the neuronal architecture of the brain,
but the cerebrovasculature as well (Grammas et al., 2002). Aβ can deposit into the walls
of the microvessels of the brain, leading to a condition known as cerebral amyloid
angiopathy (CAA) which is present in 70-90% of AD cases (Greenberg et al., 2004;
Smith and Greenberg, 2009). CAA typically affects small arteries, such as pial and
intracerebral arteries, and may be due to an age-related dysfunction in the blood-brainbarrier (BBB) that leads to impaired clearance of Aβ from the brain, further confounding
the accumulation of Aβ in aging brains (Greenberg et al., 2004; Zlokovic, 2008).
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CAA can result in cognitive impairment as it causes hypoperfusion by narrowing
the vessels (Farkas and Luiten, 2001; Smith and Greenberg, 2009; Fossati et al., 2012);
increased vulnerability to ischemic injury by reducing vascular reactivity and
compromising the structural integrity of microvessels (Zhang et al., 1997); and increased
prevalence of small hemorrhages or microbleeds, causing ischemia (Smith and
Greenberg, 2009; Armstrong, 2006; Jiwa et al., 2010). Interestingly, severe cerebral
hemorrhages are characteristic of the FAD Dutch E22Q Aβ variant (Fossati et al., 2012).
CAA is also associated with cerebral atherosclerosis, an identified risk factor for
developing AD (de le Torre, 2002; Aliev et al., 2002). Microvessels damaged by CAA
demonstrate co-localization of Aβ and oxidative stress markers (Aliev et al., 2002) as
well as inflammatory pathology (Dermaut et al., 2001), all key pathogenic factors in
neurovascular dysfunction in AD and other neurodegenerative disorders such as stroke
(Iadecola, 2010).
1.7 Neuroinflammation
Chronic inflammation - marked by microgliosis, astrocytosis, and the release of
pro-inflammatory cytokines - is a hallmark of AD brains, but it is not clear if
inflammation is the primary cause in initiating AD (Humpel, 2011) or a result of Aβ
dysregulation (Moore and O’Banion, 2002). Regardless, inflammation is a major factor
implicated in neurodegeneration in AD and aging, and is known to enhance oxidative
stress (Humpel, 2011) by up-regulating the expression of free-radical producing enzymes
and down-regulating anti-oxidant defenses (Iadecola, 2010), which can accelerate
neuronal death and the progression of AD (Herrup, 2010; Koistinaho and Koistinaho,
2005; Peila and Launer, 2006).
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Chronic neuroinflammation also leads to an increase in Aβ expression and
deposition (Goldgaber et al., 1989; Ge and Lahiri, 2002), as the amyloid deposition cycle
(Herrup, 2010) illustrates the intimate relationship between inflammation and AD
pathology: Aβ aggregates trigger a cytokine-mediated immune response, which
stimulates Aβ production and further inflammatory cell recruitment. Most amyloid
plaques are intimately associated with activated astrocytes and “frustrated microglia”
attempting to clear the plaques, however microglia are believed to play an important role
in plaque formation (Eikelenboom et al., 1994; Griffin et al., 1995). Activated microglia
secrete cytotoxins (including cox-2 and complement) and cytokines (TNF and IL-1)
(Benveniste, 1995; Giulian, 1995) in an attempt to destroy the plaques and attract other
inflammatory cells. Inadvertantly this can aggravate APP expression and Aβ generation
(Benveniste, 1995; Giulian, 1995) as well as cause neuronal death through “bystander
lysis” (Sheng et al., 2003), further perpetuating the neuroinflammatory response.
Retrospective studies found that the long-term use of non-steroidal antiinflammatory drugs (NSAIDs) lowered the risk of AD by 30-60% (McGeer et al., 1996;
Stewart et al., 1997; Vlad et al., 2008) and many hypothesized that anti-inflammatory
drugs may be used to delay AD (Perry et al., 1995; Moore and O’Banion, 2002). Antiinflammatories, including NSAIDs, have failed at preventing disease progression in
clinical trials (Van Gool et al., 2001) and some have even been detrimental (ADAPT,
2008) likely because the disease process is too far advanced when the treatment begins
(Herrup, 2010), and due to the fact that inflammation is one of the natural healing
responses of the brain.
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While AD transgenic mice fail to demonstrate neurodegeneration, they do show
Aβ plaque formation and neuroinflammation and thus are said to model early AD
(Benilova et al., 2012; Abramowski et al., 2012). Transgenic mice overexpressing APP
demonstrated enhanced sensitivity to lipopolysaccharide (LPS)-induced inflammation
(Sheng et al., 2003) and a heightened vulnerability to ischemic injury (Zhang et al., 1997;
Koistinaho et al., 2001; Whitehead et al., 2010), resulting in greater neurodegeneration
due to potentiation of the neuroinflammatory response. The enhanced neuroinflammation
was associated with increased expression of APP and accumulation of Aβ, implicating
inflammation as an etiological factor in AD by inducing excessive generation and
precipitation of Aβ species (Sheng, 2003). Aβ is not only capable of precipitating AD, it
can also act as a pathogenic substrate by potentiating the neuroinflammatory effects of
secondary insults (Pike et al., 1995; Herrup, 2010).
1.8 Stroke
Stroke is an interruption in the blood supply to the brain causing ischemia and is a
major cause of death and disability in industrialized nations (Lai et al., 2011). Subclinical,
or ‘silent’, strokes are the most common type of stroke and their prevalence increases
rapidly with increasing age (Hachinski, 2008; Vermeer et al., 2003). Depending on the
location of the stroke and the rate and duration of ischemic conditions, stroke can cause
massive cell death mediated by both necrotic and apoptotic pathways (Gabryel et al.,
2012). Necrosis occurs when cells are exposed to acute stress or energy depletion,
causing cellular swelling, edema and damage to neighbouring tissues inducing an
inflammatory response (Gabryel et al., 2012; Yamashima and Oikawa, 2009). The core of
the infarct is marked by necrotic cell death, as it is directly subjected to hypoxia and the
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effects of deleterious agents released from adjacent cells (Obrenovitch, 1995). The acute
neuroinflammatory response is marked by the adhesion and extravasation of leukocytes
and the activation, proliferation and migration of microglia to the site of damage (BruceKeller, 1999, Stoll et al., 1998; Marks et al., 2001) where they can inadvertantly
aggravate damage caused by the primary ischemic insult (Dirnagl et al., 1999).
Apoptosis is the prototypical form of cell death in the peri-infarct region, or
penumbra, where neurons are less affected by reduced oxygen and nutrient supply, and is
not accompanied by an inflammatory response or surrounding tissue damage (Taoufik
and Probert, 2008). Excluding stress proteins such as heat shock protein 70 (HSP70) and
apoptotic elements, protein synthesis is reduced in the penumbra and is one of the earliest
and most sensitive metabolic consequences of ischemia (Rebel et al., 2005).
1.9 The Ischemic Cascade: Glutamate Toxicity
The ischemic cascade is a series of biochemical events initiated within seconds
after the infarction occurs that results in the propagation of irreversible tissue damage to
the periphery of the infarct (Gabryel et al., 2012). The primary mechanism mediating
stroke damage is glutamate receptor over-activation, caused by the uncontrolled release
and extracellular accumulation of glutamate, the primary excitatory neurotransmitter in
the mammalian CNS, causing excitotoxicity and neuronal death (Reviewed Lai et al.,
2011; Lee et al., 1999; Rothman and Olney, 1995; Simon et al., 1984; Traynelis et al.,
2010; Ryan et al., 2008; Yamashima and Oikawa, 2009; Hossman, 1996). Glutamate
receptor over-activation leads to a Ca2+ influx into the cell, disrupting normal Ca2+
homeostasis and mitochondrial function, causing a massive increase in production of
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reactive oxygen species (ROS) (Yamashima and Oikawa, 2009). ROS are formed by the
partial reduction of oxygen, and can induce extensive damage to DNA, lipids, proteins
and lysosomal membranes, collectively termed oxidative stress (Yamashima and Oikawa,
2009). The brain is particularly vulnerable to oxidative stress because it is the most lipidrich organ in the body, consumes a large percentage of the total inspired oxygen and has a
relative lack of anti-oxidant defense enzymes (Coyle and Puttfarcken, 1993; Yamashima
and Oikawa, 2009). This susceptibility to oxidative stress results in secondary
neurodegeneration in the penumbra and subsequent expansion of the infarct (DelivoriaPapadopoulus and Mishra, 2000; Leon et al., 1991; Kogure and Kogure, 1997; Samdani,
Dawson and Dawson, 1997). Blocking glutamate receptors to prevent excitotoxicity has
shown to exacerbate stroke outcomes (Lai et al., 2011) likely because glutamate receptors
mediate many different neuronal functions and cannot be blocked non-specifically
without some undesired effects, making it necessary to find therapeutic targets
downstream of glutamate receptor activation.
1.10 Autophagy in Stroke
Stroke exposes neurons to a variety of different cellular stress factors and all of
which are capable of initiating autophagy, a mechanism to help cells adapt to stress by
generating metabolic substrates (Kubota et al., 2010). Autophagy has shown to be
protective following serum deprivation in neurons, as well as in animal models of
neonatal hypoxic/ischemic injury, and cerebral injury such as traumatic brain injury
(TBI) (Carloni, Buonocore and Balduini, 2008; Erlich et al., 2007; Steiger-Barraissoul
and Rami, 2009). However, the excessive activation of autophagy following cerebral
ischemia has shown to mediate neuronal death in the infarct (Koike et al., 2008; Rami et
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al., 2008; Wen et al., 2008; Puyal et al., 2009), and inhibiting autophagy suppressed
neuronal death in in vivo models of ischemia (Kubota et al., 2005; Samara, Syntichaki
and Tavernarakis, 2008; Wen et al., 2008).
Apart from complete cellular atrophy, excessive autophagic activity is believed to
partially mediate cell injury during ischemia due to the ROS-generating activity of
autophagic cellular machinery such as autophagosomes and lysosomes, as well as
mitochondria (Kubota et al., 2005). The constitutive levels of ROS produced in cells by
mitochondria and lysosomes may explain cell-susceptibility to glutamate-induced
oxidative cytotoxicity (Kubota et al., 2005), as autophagy and lysosome inhibitors were
both able to diminish glutamate-induced toxicity in vitro, as well as attenuate neural cell
death and reduce infarct volume following ischemia in rats (Kubota et al.,2005; Gabryel
et al., 2012; Puyal et al., 2009).
1.11 Stroke and AD
Strong epidemiological evidence exists that vascular risk factors are involved in
the pathogenesis of AD (Reviewed by Iadecola, 2010; Cechetto et al., 2008) as studies
indicate that AD and stroke not only share common risk factors including age,
hypertension, atherosclerosis and diabetes (Reviewed by Iadecola, 2010) but that stroke
itself greatly increases the risk of developing AD (Kalaria, 2009; Sonnen et al., 2009;
Vermeer et al., 2003; Ballard et al., 2000; Esiri et al., 1999). The prevalence of dementia
is higher in ischemic stroke patients than controls (Kalaria, 2002; Tatemichi et al., 1992),
and importantly more than half develop progressive dementia – such as AD – where the
cerebral damage is not a direct cause of the subsequent dementia, as it is in vascular
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cognitive impairment (VCI) (Tatemichi et al., 1994; Gearing et al., 1995; Hachinski,
2008). Stroke can lead to VCI depending on the location of the infarct, or as a result of
progressive neuronal loss as evidenced in multi-infarct dementia (Hachinski et al., 1974).
AD is the most common cause of senile dementia, and with VCI makes up 75% of cases
of senile dementia (Gearing et al., 1995; Hachinksi, 2008; Humpel, 2011; Wang et al.,
2010). AD can be difficult to differentiate from VCI, as stroke is the most common
comorbidity with AD as approximately 40% of AD patients present with vascular
pathology at autopsy, the majority of which are subcortical lacunar infarcts, or small
striatal strokes (Jellinger, 2008; Gearing et al., 1995; Kalaria, 2000; Heyman, 1998;
Snowdon et al., 1997). Remarkably, the coexistence of small striatal strokes in patients
with even moderate Aβ deposition had a profound effect on the severity of the dementia,
compared to patients with equivalent Aβ pathology alone (Nagy et al., 1997; Heyman et
al., 1998; Snowdon et al., 1997; Hachinski, 2008; Humpel, 2011; Whitehead et al.,
2005a).
1.12 A Comorbid Condition: Underlying Mechanisms and Overlapping Pathologies
Based on their co-morbidity and the pathological significance of their interaction,
it is imperative to study stroke and AD in a clinically relevant co-morbid animal model.
The common vascular risk factors and high comorbidity between stroke and AD indicate
related pathogenic mechanisms (De la Torre, 2002), which may explain their complex
synergistic relationship and guide new therapeutic strategies. Modeling the brain at risk
for developing dementia – where striatal stroke occurs in the presence of Aβ (Whitehead
et al., 2005a,b, 2007a) – also allows the testing of therapeutics in a preventative approach,
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as it is difficult to define AD onset as it has such a long pre-symptomatic phase (Sperling
et al., 2011; Perrin, Fagan and Holtzman, 2009).
1.13 Aβ and Stroke: AD Correlates
Stroke has shown to result in the generation of AD correlates - specifically
increased APP expression, Aβ generation and accumulation of hyperphosphorylated tau which is believed to be one way in which stroke accelerates AD progression (Kalaria et
al., 1993; Wang et al., 2010; Iadecola, 2004). It is worth noting that excessive synaptic
activity due to epilepsy or excitotoxic injury can enhance Aβ production (Herrup, 2010);
traumatic brain injury (TBI) can cause an up-regulation in APP, Aβ, β-secretase and
PSEN1 expression which largely determines the extent of the injury (Loane et al., 2009);
and LPS-induced inflammation also enhances APP expression and Aβ generation (Sheng
et al., 2003), so it is not necessarily the nature of the injury, but of the response (Herrup,
2010) that may precipitate AD if it occurs in the vulnerable brain.
The generation of Aβ following ischemia is directly correlated with secondary
neuronal loss (Zhang et al., 2010, 2011), as β-secretase activity is elevated - favouring
amyloidogenic processing of APP (Hiltunen et al., 2009) - and inhibiting Aβ production
with a γ-secretase inhibitor improved neuronal survival following stroke (Zhang et al.,
2011). Autophagy is an active pathway for Aβ production (Yu et al., 2005), and has been
shown to contribute to neuronal death following ischemia (Nixon, 2007). Inhibiting
autophagy has shown to reduce neuronal loss following stroke by reducing generation of
ROS (Kubota et al., 2010), and more recently it was shown that autophagy inhibitors
reduce β-secretase levels, inhibiting generation of Aβ and improving neuronal survival
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(Zhang et al., 2012). Thus, as we identify other pathological points of overlap we gain
new therapeutic strategies and targets.
1.14 Aβ and Stroke: Inflammation
Early co-morbid animal models used transgenic mice over-expressing APP that
were subjected to middle cerebral artery occlusion (MCAO), and discovered that the
complex pathological relationship between stroke and Aβ is bidirectional: Aβ toxicity
enhanced stroke pathology resulting in enhanced neuroinflammation, increased infarct
volume and greater neuronal loss (Zhang et al., 1997; Koistinaho et al., 2001). Aβ
toxicity is believed to enhance the effects of secondary insults primarily through
potentiation of the neuroinflammatory response (Sheng et al., 2003; Whitehead et al.,
2005a,b, 2007a; Zhang et al., 1997; Koistinaho et al., 2001; Hiltunen et al., 2009; Lai et
al., 2011), which is also believed to underlie the stroke-induced aggravation of cognitive
impairment (Li et al., 2011).
To improve the validity and clinical relevancy of this work, our lab established a
model employing small striatal infarcts, as they showed the highest correlation with
magnifying the cognitive impairment induced by Aβ toxicity (Snowdon et al., 1997;
Heyman et al., 1998). To control the age and extent of Aβ toxicity, we developed an Aβinfusion model to induce generalized Aβ toxicity via bilateral intracerebroventricular
(i.c.v.) injection of Aβ25-35, and have recapitulated the clinical phenomena: small striatal
strokes were able to enhance the effects of Aβ on cognitive impairment, and Aβ led to an
enhanced neuroinflammatory response following stroke resulting in a progressive
increase in infarct size and AD correlates (Whitehead et al. 2005a, 2007a; Cheng et al.,
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2006). Targeting the neuroinflammatory response with a variety of anti-inflammatories
has typically shown benefit for either pathology in isolation, yet when combined antiinflammatories are much less effective at ameliorating the resulting pathology
(Whitehead et al., 2005b, 2010). Thus it is important to identify other points of
pathological overlap the co-morbid condition in order to guide therapeutic strategies to
complement anti-inflammatory treatment.
1.15 Ganglioside Biochemistry
Gangliosides - complex sialic acid-containing glycosphingolipids - are
differentially expressed in all vertebrate cells and are particularly enriched in the brain
where they have regulatory roles in many physiological processes including nerve growth
and differentiation, synaptogenesis, cell signaling, neuronal plasticity and the modulation
of immune responses and cell death and survival processes (Svennerholm, 1994; Bektas
and Spiegel, 2004; Ledeen and Wu, 2004; Nakatsuji & Miller, 2001; Riboni et al., 1997).
Gangliosides are typically found in the outer cell leaflet of the plasma membrane where
they act as the functional lipid component of membrane lipid rafts (Kreutz et al., 2011).
Gangliosides are anchored into the plasma membrane by a ceramide moiety, with an
oligosaccharide tail extending into the extracellular environment that is differentially
modified by the addition of sialic acid residues (Wu et al., 2005; Malisan & Testi, 2002)
that contribute to the charge, physicochemical properties and functional implications of
gangliosides (Schauer, 1985; Riboni et al, 1995).
Gangliosides have been implicated in cell death and cell survival processes (Sohn
et al., 2006; Kreutz et al., 2011), and it is believed that they may play an important role in
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determining the neuronal response to injury due to their roles in the maintenance and
repair of nervous tissue (Furukawa et al., 2007; Kittaka et al., 2008) as well as their
regulation of cell proliferation and cell death (Giammarioli et al., 2001; De Maria et al.,
1997). Their diverse glycan structures extend into the extracellular space and function in
cell-cell recognition and as receptors or co-receptors for many ligands such as cytokines,
toxins, hormones and viruses (Bergelson, 1995), and through their lateral association with
signaling molecules in the plasma membrane gangliosides can impact global cellular
events (Lopez and Schnaar, 2009).
Gangliosides are also found in blood plasma and the cerebrospinal fluid (CSF),
and there is a constant exchange between cell-associated and non-cell-associated
gangliosides meaning they can be ‘shed’ from the cell surface into the extracellular space
during cell membrane turnover, and exogenous gangliosides can be incorporated back
into the plasma membrane (Malisan & Testi, 2002; Bergelson, 1995). Degenerative
processes in the CNS are associated with an increased shedding of membrane fragments,
as cellular degeneration leads to an increased turnover of cell membranes and subsequent
release of gangliosides (Miyatani et al., 1990; Trbojevic-Cepe et al., 1991; TarvonenSchroder et al., 1997; Andersson et al., 1998).
1.16 Ganglioside Expression and Synthesis
Ganglioside biosynthesis occurs in a step-wise manner beginning in the early
Golgi apparatus with the glycosylation of ceramide (Malisan & Testi, 2002; Daniotti and
Bartolome, 2011) (Fig. 1a). GM3 is the simplest ganglioside and is the common
precursor for ganglioside biosynthesis (Ju et al., 2005). Through the sequential addition
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Figure 1 - Ganglioside metabolism. Ganglioside expression is a dynamic process with
regulatory roles in the differentiation, development and repair of CNS tissue. A)
Biosynthesis occurs along the secretory pathway, starting with the glycolysis of ceramide,
followed by the sequential addition of sugar residues and sialic acid residues resulting in
a high diversity of final products expressed in the outer cell membrane or released into
the extracellular space. B) Catabolism is an endocytosis- and lysosome-dependent
process, generating partial or full degradation products that are recycled for ganglioside
biosynthesis or other synthetic pathways throughout the cell. Adapted from Daniotti and
Bartolome, 2011.
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of carbohydrates and sialic acid residues to GM3, with each step regulated by specific
membrane-bound glycosyltransferases, cells can generate the a-, b- and c- series of
gangliosides (Malisan & Testi, 2002) (Fig.1a).
It is established that ganglioside expression is a dynamic process, representing a
cell’s adaptation to environmental conditions with expression profiles changing
drastically during development, the cell cycle, differentiation and disease (Nagai, 1995;
Nakatsuji & Miller, 2001; Svennerholm, 1980; Vyas and Schnaar, 2001; Mocchetti,
2005; Lopez and Schnaar, 2009; Yu et al., 2012). The embryonic vertebrate brain is
characterized by an abundance of simple gangliosides such as GM3 and GD3
(Stojiljkovic et al., 1996; Yu et al., 1988; Ju et al., 2005), while at later developmental
stages complex gangliosides dominate, specifically the major brain gangliosides GM1,
GD1a, GD1b and GT1b (Reviewed by Yu et al., 2012). GM3 is typically below detection
threshold in the healthy adult mouse (Whitehead et al., 2011) and human brain (Marconi
et al., 2005).
Studies investigating the in situ expression of gangliosides in normal and
pathologic CNS conditions often demonstrate conflicting results with in vitro studies, as
culture conditions may modulate the biological properties of cells, in particular the
expression of glycolipids (Marconi et al., 2005; Kawai et al., 1999; Nardelli et al., 1994).
Marconi et al. (2005) demonstrated that in the post-mortem brains of adult humans who
died of both non-neurological diseases and neurological diseases (progressive multiple
sclerosis, AD, amyotropic lateral sclerosis and stroke) GFAP-positive astrocytes
expressed GM1, GD1b and GD3, which is a minor ganglioside in most tissues but is
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highly expressed in the placenta and thymus, while reactive microglia were GD1a
positive; however neither astrocytes nor microglia expressed GM3.
1.17 Ganglioside Catabolism
Ganglioside catabolism is an endocytosis- and lysosome-dependent process that
generates degradation products to be recycled throughout the cell for biosynthesis
(Malisan & Testi, 2002; Pitto et al., 2004) (Fig. 1b). The catabolism pathway is the same
for cell-associated and non-cell associated gangliosides, however non-cell associated
gangliosides must first be incorporated into the plasma membrane; from there complex
gangliosides undergo endocytosis and are delivered mainly to lysosomes where
degradation occurs (Pitto et al., 2004). Similar to ganglioside synthesis, catabolism is a
step-wise process where sialic acid and sugar residues are sequentially removed by
specific enzymes (Sandhoff and Kolter, 2003; Miyagi et al., 1999). Partial degradation
products can be routed out of lysosomes into salvage pathways directly for ganglioside
biosynthesis, or undergo complete degradation in the lysosomes where end products, such
as sphingosine, can be recycled for synthesis of other biomolecules such as
sphingomyelin (Riboni et al., 1991; Malisan & Testi, 2002; Tettamanti, 2004; Kolter and
Sandhoff, 2010; Sandhoff and Kolter, 2003; Tettamanti et al., 2003). In slowly dividing
cells the recycling pathway is predominant, while rapidly dividing cells favour the de
novo synthesis of gangliosides (Gillard et al., 1998).
Complex gangliosides in the CNS are first degraded to GM1 by the sequential
removal of sialic acid residues by a membrane-bound sialidase (Miyagi et al., 1999;
Prokazova et al., 2009; Ledeen, 1990; Furst and Sandhoff, 1992), which can occur
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outside of the lysosome at the plasma membrane (Riboni et al., 1995). Further
degradation beyond GM1 is lysosome dependent, where the lysosomal glycosidase βgalactosidase degrades GM1 to GM2, and GM2 to GM3, before the final sialic acid
residue can be removed (Van Echten and Sandhoff, 1993; Sandhoff and Kolter, 2003;
Riboni et al., 1995). Inhibiting endocytosis with low temperatures, or lysosomal activity
with Chloroquine - a lysomotropic agent that raises lysosomal pH - prevents the
appearance of GM3 as well as formation of any degradation products downstream of
GM1 (Fig. 1b) (Riboni et al., 1995).
1.18 Defects in Gangioside Metabolism
Genetic defects in ganglioside metabolism can lead to severe complications and
disease, however the majority of human diseases associated with ganglioside metabolism
are caused by defects in catabolism; human diseases associated with impaired ganglioside
synthesis are much rarer (Simpson et al., 2004; Dawkins et al., 2001).
In genetically altered mice that lack the ability to synthesize complex gangliosides
(GalNac-T KO) or their precursors (GlcCer-T KO), it has been demonstrated that
gangliosides are essential for embryonic development (Yamashita et al., 1999) and that
complex gangliosides play an important role in the maintenance and repair of nervous
tissue, evidenced by neurodegenerative changes after birth (Furukawa et al., 2007;
Yamashita et al., 1999; Ohmi et al., 2011; Jennemann et al., 2005). GalNac-T KO mice
displayed normal brain morphology at birth, but impaired intracellular Ca2+ homeostasis
led to increased neuronal susceptibility to apoptosis along with CNS impairment,
neurodegeneration and shorter lifespans (Wu et al., 2001; Chen et al., 2005; Furukawa et
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al., 2007; Yamashita et al., 1999; Takamiya et al.,1996; Sheikh et al., 1999; Wu et al.,
2005).
The mechanisms behind the degenerative changes in these genetically altered
mice are not entirely clear, but evidence suggests complex gangliosides regulate Ca2+
homeostasis (explaining the increased susceptibility to apoptosis) (Wu et al., 2004; Wu et
al., 2005; Wu et al., 2001) and activation of the complement system by maintaining lipid
raft integrity (Furukawa et al., 2011; Okada et al., 2002). Neurodegeneration is likely
confounded in these genetically altered mice based on the finding that complex
gangliosides also play a role in the ability of astrocytes to support neuronal survival
(Akasako et al., 2011). Cultured astrocytes that were treated with d-1-phenyl-2decanoylamino-3-morpholino-1-propanol (d-PDMP), a synthetic ceramide analogue that
inhibits glucosylceramide synthesis (Fig. 1b) and depletes all endogenous gangliosides
(Inokuchi et al., 1989; Inokuchi and Radin, 1987), showed reduced capacity to support
neuronal survival (Akasako et al., 2011). d-PDMP was also shown to inhibit functional
synapse formation and reduce neurite outgrowth in cultured neurons from wild-type rats,
indicating that complex gangliosides are important for proper CNS functioning (Mizutani
et al., 1996; Inokuchi et al., 1997; Harel and Futerman, 1993).
1.19 Lysosomal Storage Diseases
The impaired ability to degrade gangliosides leads to the accumulation of
gangliosides and secondary metabolites (Walkley, 2004) - such as cholesterol (LloydEvans and Platt, 2010) – within endosomal or lysosomal compartments, and is
characteristic of severe conditions known collectively as lysosomal storage diseases
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(LSDs) which can result in cognitive impairments and early lethality (Patschan et al.,
2008; Vitner et al., 2010; Kolter and Sandhoff, 2010; Sandhoff and Kolter, 2003; Marks
and Pagano, 2002; Schuette et al., 1999). LSDs can be due to inherited genetic defects in
enzymes responsible for the degradation of gangliosides, such as β-galactosidase which
results in the accumulation of GM1 (GM1 gangliosidosis) (Vitner et al., 2010), or in
cholesterol trafficking defects downstream of impaired lysosomal functioning as in
Niemann Pick C disease (Lloyd-Evans et al., 2008) which also leads to the accumulation
of gangliosides (Vitner et al., 2010). The accumulation of gangliosides within endosomal
compartments initiates an inflammatory response in both the periphery and the CNS, and
inflammation often precedes the onset of other symptoms (Jeyakumar et al., 2003). In
addition to inflammation, GM1 gangliosidosis also displays oxidative stress, endoplasmic
reticulum (ER) stress, altered calcium homeostasis, autophagy and altered lipid
trafficking (Reviewed by Vitner et al., 2010).
Reduced proteolytic activity associated with aging can also lead to the
accumulation of gangliosides, a process that is associated with cell senescence that can
activate apoptosis (Kurz et al., 2000; Malisan and Testi, 2002; Sano et al., 2009). In this
regard, AD resembles an adult-onset lysosomal storage disease (Pasternak et al., 2003),
as cells lose the ability to efficiently degrade Aβ and hyperphosphorylated tau, which
eventually reach neurotoxic concentrations both inside and outside of the cell (Daniotti
and Bartolome, 2011).
Interestingly, the enantiomeric form of d-PDMP, l-PDMP, has been shown to
increase the biosynthesis of gangliosides (Inokuchi et al., 1989,1995) by up-regulating
glucosylceramide synthesis, which is responsible for ganglioside biosynthesis (Inokuchi,
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2009). Adding l-PDMP to cultured neurons resulted in functional synapse formation
(Inokuchi et al., 1997) and stimulated neurite outgrowth (Usuki et al., 1996) showing it
was possible to augment normal levels of gangliosides in neurons and thereby produce
beneficial effects (Inokuchi et al., 1997).
It’s been demonstrated that ischemia reduces ganglioside levels (Rastogi et al.,
1968; Domanska-Janik et al., 1982; Qi and Xue, 1991; Ramirez et al., 2003), and lPDMP was effective at ameliorating the spatial memory deficit induced by MCAO in rats
(Inokuchi et al., 1997; Yamagishi, 2003) and prevented apoptosis in the hippocampus,
even when administered 24 hours after ischemia (Inokuchi, 2009). L-PDMP is believed
to improve neurological outcome following stroke by increasing ganglioside
biosynthesis, as gangliosides promote neurite outgrowth and recovery (Inokuchi et al.,
1997; Yamagishi et al., 2003; Usuki et al., 1996; Iwasaki et al., 1998). Exogenous
gangliosides can also elicit neurite outgrowth and neural repair in vitro and in vivo (Pepeu
et al, 1994; Tsuji et al., 1992; Wu et al, 1991) as well as attenuate serum-deprivation
induced neuronal apoptosis (Ryu et al., 1999). It is important to note that gangliosides do
not function as neurotrophic factors themselves, but act by potentiating neurotrophic
influences present in the CNS (Ariga et al., 2010).
1.20 GM1 and GD1b Mediate Prosurvival Processes
GM1 is one of the major brain gangliosides and has demonstrated neuroprotective
as well as neurotrophic effects in a variety of paradigms (Yu et al., 2009). GM1 has been
shown to potentiate neurotrophin release and action, exert anti-oxidant effects, modulate
signaling pathways involved in death processes, and dose-dependently reduce glutamate-
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induced excitotoxicity in vitro and in vivo (Yu et al., 2009; Rabin et al., 2002; Mocchetti,
2005; Fighera et al., 2004; Furian et al., 2007; Gavella et al., 2007; Cunha et al, 1999;
Mutoh et al., 1995; Pitto et al., 1998; Lili et al., 2005; Carolei et al., 1991; Fusco et al.
1993; Leon et al., 1991). GM1 effectively decreased the severity of ischemic brain
lesions in experimental models (Frontczak-Baniewicz et al, 2000; Hicks et al, 1998;
Yamagishi et al., 2003), and while its mechanism is not clear, GM1 works downstream of
glutamate receptor over-activation and is related solely to the limitation of intracellular
events (Carolei et al., 1991; Daniotti & Bartolome, 2011).
GM1 showed therapeutic promise as its systemic administration could not only
effectively reduce acute neuronal damage by attenuating excitotoxicity, but could also
facilitate long-term functional recovery after brain injury by potentiating the effects of
neuronotrophic factors (Carolei et al., 1991; Daniotti & Bartolome, 2011), which led
some to postulate that GM1 may be effective in treating AD (Biraboneye et al, 2009).
GM1 proved less effective in human studies however, as it was tested in over 2000
patients across twelve trials for stroke and showed no functional benefit (Candelise and
Ciccone, 2002), as well as potential aversive side effects as anti-GM1 antibodies are
associated with the neurological disorder Guillan-Barre Syndrome (Nores et al., 2008;
Willison and Yuki, 2002; Zhang and Kiechle, 2004).
The predominant expression of b-series gangliosides - of which GD1b belongs was shown to reduce ceramide-induced apoptosis (Bieberich et al., 2001). Excessive K+
efflux promotes apoptosis in almost all cell types (Hribar et al., 2004) and neurons
(Reviewed by Chen et al., 2005), and K+ channel blockers have been shown to be able to
suppress apoptosis (Yu, Canzoniero and Choi, 2001; Yu et al., 1997). After exogenous
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administration of the major brain gangliosides, GD1b was the only ganglioside capable of
suppressing staurosproine-induced apoptosis by inhibiting K+ efflux (IK) (Chen et al.,
2005).
1.21 Gangliosides Affect Aβ Fibrillization and Expression
The fibrillization of amyloid is believed to be a key step in the pathogenesis of
AD (Yu et al., 2012; Yanagisawa et al., 1995; Yanagisawa and Ihara, 1998; Hayashi et
al., 2004) and appears to be mediated by gangliosides. Ganglioside-bound Aβ (GAβ) was
first discovered in brains with early pathological AD changes (Yanagisawa et al., 1995)
and led to the GAβ hypothesis: Aβ binds to ganglioside clusters on neuronal membranes
forming GAβ, which alters the conformation of Aβ and acts as an endogenous seed in the
brain facilitating amyloid fibril formation from soluble Aβ species (Yangaisawa et al.,
2005, 2011). The formation of unique ganglioside clusters that induce GAβ formation are
likely influenced by risk factors for AD, specifically aging and ApoE4 (Yamamoto et al.,
2004), and facilitated by endocytic pathway abnormalities observed in AD brains
(Cataldo et al., 2000; Yuyama et al., 2006, 2008; Yuyama & Yanagisawa, 2009). GM1 is
able to bind Aβ (Yanagisawa et al, 1995; Wakabayashi et al., 2005; Okada et al., 2007)
and among all of the major brain gangliosides, demonstrates the greatest seeding
potential, or ability to induce fibrillization of Aβ (Yanagisawa, 2011). GM1 is present in
amyloid plaques bound specifically to Aβ (Yanagisawa et al. 1995; Yanagisawa and
Ihara, 1998).
One experiment demonstrated that exogenous GM1 reduced plaque load in the
brains of APP transgenic mice, however this is likely a result of GM1 sequestering
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peripheral Aβ (Matsuoka et al., 2003), as the exogenous administration of GM1 to cells
overexpressing APP has shown to drastically increase Aβ secretion while attenuating
sAPPα secretion (Tamboli et al., 2008; Grimm et al., 2012; Zha et al., 2004). d-PDMP
was able to reduce secretion of Aβ, which was reversed by the addition of exogenous
gangliosides (Tamboli et al., 2005). It is suggested that gangliosides are involved in the
subcellular transport of APP, and hence affect its proteolytic processing (Tamboli et al.,
2005, 2008). Double transgenic mice expressing APP and PSEN1 mutations exhibit
memory impairments and Aβ pathology, while triple transgenic mice expressing the same
AD mutations, but also lacking GD3 synthase and therefore complex b-series
gangliosides, perform as well as wildtype mice and the Aβ pathology and behavioural
impairments are almost completely eliminated (Bernardo et al., 2009). The mechanism is
far from clear how altered ganglioside biosynthesis leads to the elimination of Aβ.
1.22 GM3
GM3 is the simplest ganglioside and the common precursor for ganglioside
biosynthesis, however it is normally only expressed in the brain during embryonic
development and is below detection threshold in the healthy adult mouse (Whitehead et
al., 2011) and adult brain (Ju et al., 2005; Stojilikovic et al. 1996; Marconi et al., 2005).
GM3 is the major serum ganglioside however, and is highly expressed in endothelial cells
where it has been shown to inhibit angiogenesis in vivo (Lopez & Schnaar, 2009),
suggesting a regulatory role. GM3 is used as a serum biomarker of metabolic syndrome,
as it correlates with LDL cholesterol levels (Inokuchi, 2011) and is an inducer of insulin
resistance (Ryden and Arner, 2007). Diabetes mellitus, or type 2 diabetes, is a major risk
factor for stroke that also increases AD morbidity (Iadecola, 2010), and has been re	
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envisioned as a membrane microdisorder caused by the aberrant expression of
gangliosides, specifically GM3 (Inokuchi, 2011). Elevated GM3 concentrations in the
cerebrospinal fluid (CSF) correlate with BBB dysfunction, and may be an indicator of
cerebral hemorrhage, compressive syndromes or brain melanoma (Trbojevic-Cepe et al.,
1991). Once again, degenerative processes in the CNS lead to the increased shedding of
membrane fragments and gangliosides into the intercellular space (Miyatani et al., 1990;
Trbojevic-Cepe et al., 1991; Tarvonen-Schroder et al., 1997; Andersson et al., 1998;
Malisan and Testi, 2002). GM3 is also the major ganglioside in monocytes and
lymphocytes (Kiguchi et al., 1990) and is believed to control differentiation of peripheral
monocytes into macrophages - a critical process in the development of the inflammatory
reaction (Gracheva et al., 2009) – as GM3 is enhanced in atherosclerotic lesions
(Bobryshev et al., 1997). GM3 expression can be influenced by inflammatory cytokines
(Inokuchi, 2011) as tumour necrosis factor α (TNFα) – a multifunctional cytokine with a
well-established role in inflammation (Prokazova et al., 2009) - increases expression of
GM3 in adipocytes, and TNFα-induced insulin resistance was prevented by decreasing
GM3 levels with d-PDMP (Inokuchi et al., 2011). While the relationship is not fully
understood, GM3 is also believed to be involved in the regulation of TNFα expression
(Prokazova et al., 2009).
GM3 is being investigated as a potential anti-tumour therapy as it has shown the
ability to prevent angiogenesis in vivo (Lopez & Schnaar, 2009) and has effectively been
shown to inhibit cell proliferation and induce apoptosis (Nagata, 1996; Nachbur et al.,
2006) in human brain tumours and gliomas (Nakatsuji & Miller, 2001; Nakamura et al.,
1991). Since exogenous gangliosides can be incorporated into the plasma membrane and
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internalized by endocytosis to be degraded and recycled throughout the cell (Malisan &
Testi, 2002), it was believed that GM3 induced apoptosis through ceramide, a
degradation product of GM3 that is involved in growth suppression and apoptosis (Obeid
et al., 1993; Pushkareva, Obeid and Hannun, 1995). An inhibitor of lysosomal
glucocerebrosidase, conduritol beta-epoxide (CBE), which prevents the conversion of
glycosylceramide to ceramide, however did not prevent the GM3-induced apoptosis and
inhibition of proliferation (Schwarz et al., 1995), suggesting GM3 induces apoptosis
through a separate mechanism.
1.23 GM3: Tombstone or Trigger?
The role of GM3 in cell death was initially unclear, as several groups
demonstrated that neurons undergoing apoptosis or glutamate toxicity increased GM3
expression (Ju et al., 2005; Sohn et al., 2006; Kreutz et al., 2011) and that GM3
accumulates in stroke and AD brains (Kracun et al., 1991; Kwak et al., 2005; Whitehead
et al., 2011) but that didn’t answer whether GM3 was the trigger, or merely the
tombstone, of cell death. Follow-up experiments showed that GM3 plays a direct role in
mediating neuronal cell death, as endogenous (Sohn et al., 2006) or exogenous (Nakatsuji
and Miller, 2001) increases in GM3 levels led to neuronal death. Exogenous GM3 was
able to induce apoptosis in all classes of neural cells, yet active proliferating cells were
more susceptible to GM3 than post-mitotic neurons (Nakatsuji & Miller, 2001). GM3
accumulation following glutamate-toxicity has been shown to mediate the massive
production of ROS (Sohn et al., 2006), which leads to cell death following stroke
(Gabryel et al., 2012). Depleting endogenous gangliosides with d-PDMP prevented the
accumulation of GM3 and the production of ROS, and improved neuronal survival (Sohn
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et al., 2006). Previous evidence demonstrated that augmenting ganglioside levels could
lead to beneficial effects (Inokuchi, 1997), and it was concluded that controlling GM3
levels should be a new therapeutic focus in managing neurodegenerative disorders (Sohn
et al., 2006).
1.24 GM3 in AD & Stroke
Mounting evidence suggests the aberrant expression of gangliosides, specifically
GM3, is involved in the pathogenesis of both stroke and AD, yet it is not clear if it is a
point of pathological synergism as it has not been studied in a comorbid model. GM3 has
been shown to accumulate in the infarct following MCAO (Kwak et al., 2005; Whitehead
et al., 2011) and in cortical areas of neurodegeneration in AD brains (Kracun et al.,
1991). The first group to demonstrate GM3 accumulation in the infarct theorized it may
be a neuroprotective response and represent an up-regulation in ganglioside biosynthesis
(Kwak et al., 2005). More recently, the accumulation of GM3 at the border of the infarct
was suggested to play a role in the expansion of the infarct (Whitehead et al., 2011) due
its role in mediating glutamate toxicity (Sohn et al., 2006). It is not clear if Aβ toxicity
will enhance the stroke-induced accumulation of GM3, or how GM3 expression will
relate to complex ganglioside expression or neuronal survival.
The concentrations of major gangliosides are altered in the brains of AD patients
and transgenic mouse models (Kracun et al., 1991; Molander-Melin et al., 2005; Barrier
et al., 2007). Specifically, GM3 has shown to accumulate in cortical areas of AD brains
associated with neurodegeneration, while complex ganglioside levels were all decreased
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(Kracun et al., 1991). Kracun et al. (1991) hypothesized that GM3 accumulation in AD
brains may be the result of accelerated lysosomal degradation of complex gangliosides.
This hypothesis was tested in an ex vivo model of AD, which has also been used
to examine biochemical alterations in APP metabolism, anti-oxidant defense and various
enzymatic activities in AD (Pitto et al., 2005). β-galactosidase, the lysosomal glycosidase
responsible for the hydrolysis of GM1 to GM2, and GM2 to GM3 (Van Echten and
Sandhoff, 1993), was assayed in fibroblasts from AD patients against age-matched
controls by incubating cultured fibroblasts with radiolabelled exogenous GM1 (Pitto et
al., 2005). Fibroblasts from AD patients not only showed enhanced formation of GM2
and GM3 compared to age-matched controls (Emiliani et al., 2003), but the extent of
GM1 hydrolysis correlated with the severity of dementia (Pitto et al., 2005). One possible
mechanism is GM3 accumulation appears to facilitate CAA in APP transgenic mice, as
high levels of GM3 in vascular and parenchymal tissues was associated with increased
levels of deposited Aβ in vascular tissues (Oikawa et al., 2009; Yu et al., 2012). CAA can
lead to microvessel damage resembling atherosclerotic lesions (Greenberg et al., 2004),
and GM3 expression is elevated in atherosclerotic lesions (Gracheva et al. 2009;
Bobryshev et al., 1997), which also increases the risk of microbleeds or ischemic
hemorrhage. Therefore GM3 levels, indicative of metabolic syndrome and cardiovascular
risk factors such as LDL cholesterol and diabetes mellitus (Inokuchi, 2011), may also
represent a unique serum biomarker for AD risk.
Aβ can also directly affect GM3 expression, as an in vitro study found that
incubating hippocampal slices with pre-aggregated Aβ25-35 led to a concomitant increase
in GM3 expression and propidium iodide uptake, indicative of peptide-induced cellular
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death (Kreutz et al., 2011). Interestingly, soluble Aβ25-35 led to an increase in GM1 and
GD1b expression and failed to induce cell death (Kreutz et al., 2011), indicating a prosurvival response in ganglioside expression. Soluble Aβ, but not inverted or aggregated
Aβ, is able to bind GM3 and inhibit the conversion of GM3 to GD3 by GD3 synthase
(Grimm et al., 2012), which is necessary for generating the b-series gangliosides and
some of the major brain ganglioside species such as GD1b and GT1b (Lahiri and
Futerman, 2007) which may be another explanation for the accumulation of GM3 in AD
brains.
1.25 Chloroquine
Chloroquine (CQ), 7-chloro-4-(-4-dietylamino-1-methylamino) quinolone, is
established as a widely used anti-malarial drug and is also used as an anti-rheumatic
agent due to its anti-inflammatory properties (Zhang et al., 2002). CQ freely diffuses
across lipid bilayers as it is uncharged at neutral pH, but is a weak base and becomes
protonated upon entering acidic compartments such as lysosomes (Fig. 2), causing it to
accumulate in acidic organelles and raise their pH above their acidic optimum (Poole and
Ohkuma, 1981; Abraham and Hendy, 1970; Zhang, 2002). This disrupts the normal
function of acidic lysosomal enzymes such as β-galactosidase (Seglen and Gordon,
1980), and has been used to inhibit the catabolism of gangliosides in vitro and other
lysosome-dependent processes such as autophagy (Riboni et al., 1991,1995; Shacka et al.,
2006). CQ is able to cross the blood-brain-barrier (BBB) (Onyegbule et al., 2010), has a
long serum half-life of approximately 5 days in man (Tracy and Webster, 1996) and has
been shown to prevent BBB dysfunction (Mielke et al., 1997) as well as attenuate
glutamate-induced oxidative stress in hippocampal cells (Hirata et al., 2011).
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Figure 2 - Chemical structure of Chloroquine. Chloroquine (CQ), 7-chloro-4-(-4
diethylamino-1-methylamino) quinolone, is uncharged at neutral pH, allowing it to
diffuse freely across lipid bilayers into organelles such as the lysosome. In acidic
environments, CQ gets protonated and is unable to diffuse through lipid bilayers, causing
it to accumulate and effectively raise the pH of acidic organelles such as the lysosome.
Adapted from Weber, Levitz and Harrison (2000).
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As previously indicated, ganglioside catabolism is an endocytosis and lysosome-

dependent process as gangliosides are first internalized into endosomes then sent to the
lysosomes, and in vitro if cells are treated with CQ then the formation of all degradation
products downstream of GM1 (i.e. GM2, GM3) is prevented (Riboni et al., 1991, 1995).
β-galactosidase is responsible for the hydrolysis of GM1 and while it cannot be targeted
directly by pharmacological inhibition, CQ disrupts β-galactosidase activity and has
shown to lead to the accumulation of GM1 in early endosomes and on the surface of cells
(Yuyama et al., 2006). Other groups have used CQ in an attempt to increase GM1
expression, which can promote acute neuroprotection and long-term functional repair
(Hirata et al., 2011). Other autophagy inhibitors have been effective at reducing infarct
volume and secondary neuronal death (Kubota et al., 2010; Gabryel et al., 2012; Puyal et
al., 2009) yet their effects on the pathological accumulation of GM3 and expression of
complex gangliosides - which are important for the maintenance and repair of CNS tissue
- are not clear. Evidence that complex ganglioside levels are reduced following stroke
(Ramirez et al., 2003) and that GM3 accumulates following stroke (Kwak et al., 2005;
Whitehead et al., 2011) suggests that GM3 accumulation is the result of the accelerated
degradation of complex gangliosides. Therefore CQ may be effective at inhibiting the
accumulation of GM3 and maintaining expression of complex gangliosides, making it an
ideal therapeutic candidate for the treatment of stroke.
1.26 Rationale
Stroke is a major risk factor for developing AD as the two pathologies share
common risk factors and demonstrate a high co-morbidity (Iadecola, 2010; Kalaria,
2009). When small striatal infarcts occur in the presence of Aβ they enhance the severity
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of cognitive impairment (Snowdon et al., 1997; Heyman et al., 1998), and conversely Aβ
enhances stroke pathology and neuronal loss through potentiation of the
neuroinflammatory response (Koistinaho et al., 2001; Whitehead et al., 2005a,b, 2007).
To be consistent with the epidemiological findings our lab developed a model of
unilateral striatal infarct achieved via targeted injection of the potent vasoconstrictor
Endothelin-1 (ET-1) which produceds transient local ischemia and a focal infarct
(Whitehead et al., 2005a, b, 2007; Jiwa et al., 2010; Lecrux et al., 2008) with reperfusion
occurring approximately one hour after ET-1-induced ischemia (Gelb et al., 2002). To
compare the effects of Aβ on striatal stroke we developed a non-transgenic model of
generalized Aβ toxicity achieved via bilateral intracerebroventricular injections of the
neurotoxic Aβ25-35 peptide (Whitehead et al., 2005a,b, 2007).
Inflammation represents a mechanistic point of overlap between the two
pathologies and is regarded as the primary mechanism behind their synergistic interaction
and neurodegeneration (Koistinaho and Koistinaho, 2005; Li et al., 2011). OX-6 staining
will serve as a correlate of neuroinflammation by identifying ramified microglia (Vinet et
al., 2012) while the mature neuronal marker NeuN will be used to assess neuronal loss
along with FluoroJade B, a non-specific marker of cellular degeneration (Schmued and
Hopkins, 2000; Damjanac et al., 2006). Anti-inflammatories are unable to ameliorate the
effects when the two pathologies are combined (Whitehead et al., 2005b, 2010), so the
search to identify mechanisms underlying the interaction is paramount to guide
therapeutic strategies and identify new targets.
Gangliosides are glycosphingolipids expressed by all vertebrate cells that are
abundant in the CNS (Svennerholm, 1980), where they are involved in cell death and cell
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survival processes and may determine the neuronal response to injury (Nakatsuji and
Miller, 2001; Bektas and Spiegel, 2004). The aberrant expression of GM3 is associated
with both stroke and AD, as GM3 accumulates in the infarct following stroke (Kwak et
al., 2005; Whitehead et al., 2011) as well as in cortical regions in AD brains marked by
neurodegeneration (Kracun et al., 1991). Evidence indicates that GM3 accumulation is
the result of accelerated lysosomal degradation of complex gangliosides (Ramirez et al.,
2003; Pitto et al., 2004), and not a result of increased biosynthesis. The accumulation of
GM3 causes neuronal death both in vitro and in vivo (Ju et al., 2005; Sohn et al., 2006;
Nakatsuji and Miller, 2001), and has shown to mediate the production of ROS following
glutamate toxicity (Kreutz et al., 2011), which is the primary mechanism mediating the
propagation of stroke damage (Simon et al., 1984; Lai et al., 2011). It is unclear
1)whether Aβ toxicity can enhance the expression of GM3 following stroke, 2) how
complex ganglioside expression is affected and 3) whether GM3 is a potential therapeutic
target. Thus GM3 expression will be assessed along with the complex gangliosides GM1
and GD1b via immunohistochemistry.
Chloroquine, a well-established anti-malarial drug and lysomotropic agent
(Riboni et al., 1995), represents a novel therapeutic for the treatment of stroke as it has
anti-inflammatory effects and has shown to reduce glutamate-induced toxicity in vitro
(Hirata et al., 2011). Chloroquine impairs lysosomal activity by raising their pH above
the acidic optimum of many lysosomal enzymes, and has been used to inhibit the
degradation of complex gangliosides and generation of GM3 in vitro (Riboni et al.,
1991,1995) however it has never been demonstrated whether it can prevent the
accumulation of GM3 following stroke in vivo. Therefore Chloroquine may improve
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neuronal survival in a comorbid model by inhibiting the degradation of complex
gangliosides, thus preventing the accumulation of GM3, and by reducing inflammation.
1.27 Hypothesis
Aβ toxicity will enhance the stroke-induced pathological accumulation of GM3,
reducing expression of complex gangliosides and in turn enhancing neuronal loss; and
Chloroquine will reduce neuronal loss by preventing the accumulation of GM3 and
reducing inflammation.
The following experiments will focus on three aims:
1) Confirm GM3 expression in our ET-1 induced striatal stroke model, and
characterize the resulting pathology and expression of complex gangliosides GM1
and GD1b in the infarct.
2) Characterize GM3 expression patterns at 3 and 21 days after inducing stroke, as
well as the cellular expression profile of GM3 by immunofluorescence.
3) Determine if CQ can prevent the accumulation of GM3 and reduce neuronal loss
at 3 and 21 days after inducing stroke.
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Section 2

METHODS
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2.1 Animals
All experimental procedures were in accordance with guidelines of the Canadian
Council on Animal Care and approved by Western University Animal Use Subcommittee
(see attached certificate, Appendix). Adult male Wister rats weighing 300-400g (Charles
River Laboratories, Quebec, Canada) were housed in pairs under standard conditions
(12:12 LD cycle) and provided food and water ad libitum. Subjects were randomly
assigned to their treatment groups and were housed individually following surgery.
2.2 Surgery
Rats were weighed before being anaesthetized in a Harvard anesthesia box with
3% Isoflurane in 2 L/min oxygen and placed in a Kopf stereotaxic apparatus. Using an
operating microscope, the Bregma was exposed to map and mark injection sites.
Injections were administered with a Hamilton glass syringe at a rate of 1 µL/30 seconds
(details below). The syringe was left in place for 3 minutes after each injection and then
slowly removed. Body temperature was maintained at 37°C on a heating pad during the
surgical and recovery periods before being returned to a cage.
Animals were assigned randomly to the following treatment groups with
coordinates relative to Bregma (Paxinos & Watson, 1986) (see Table 1 for n values):
Amyloid toxicity (Aβ): Animals received 15 µL bilateral i.c.v injections of the toxic Aβ
fragment, Aβ25-35 (5mmol) at coordinates -0.8 mm (anterior/posterior), ±1.4 mm
(medial/lateral) and -4.0 mm (dorsal/ventral). Aβ25-35 (Sigma-Aldrich Co., St. Louis,
USA) was dissolved in sterile water and stored at -80°C in 30 µL aliquots and kept on dry
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ice right up until injection to prevent aggregation and allow better diffusion throughout
the ventricles (Whitehead et al., 2005a, b, 2007).
Stroke (ET-1): Animals received a 3 µL unilateral injection of the potent vasoconstrictor
endothelin-1 (60 pmol) into the right striatum, at coordinates 0.5 mm (anterior/posterior),
-3.0 mm (medial/lateral) and -5.0 mm (dorsal/ventral). Endothelin-1 (Sigma-Aldrich Co.,
St. Louis, USA) was in dissolved in sterile water and stored at -80°C in 3 µL aliquots and
kept on dry ice right up until injection. Targeted injections of Endothelin-1 produces
transient local ischemia and a focal infarct in rats (Whitehead et al., 2005a, b, 2007; Jiwa
et al., 2010; Lecrux et al., 2008).
Combined treatment (Aβ/ET-1): Animals received bilateral i.c.v. injections of Aβ25-35
followed by a unilateral Endothelin-1 injection into the striatum at the same
concentrations and coordinates as above.
Reverse peptide (Reverse): Animals received 15 µL bilateral i.c.v. injections of the
reverse β-amyloid fragment Aβ35-25 (5mmol), at coordinates -0.8 mm (anterior/posterior),
±1.4 mm (medial/lateral) and -4.0 mm (dorsal/ventral). Aβ35-25 (Sigma-Aldrich, St. Louis,
USA) was stored at -80°C in 30 µL aliquots and kept on dry ice up until injection.
2.3 Chloroquine Administration
Chloroquine (Sigma-Aldrich, St. Louis, USA) was prepared daily at a
concentration of 50 mg/mL in 0.9% saline. Animals were weighed immediately prior to
injection and were administered 45 mg/kg of CQ by intraperitoneal (i.p.) injection for
seven consecutive days beginning three days before the surgery (Fig. 3). Dosages above
60 mg/kg in rats were associated with toxic accidents (Del Pino et al.), and at 75 mg/kg
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Figure 3 - Chloroquine administration schedule. Chloroquing treatment began 3 days
before surgery, and was administered daily at 45 mg/kg i.p. for seven days.
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acute toxicity related to the cardiovascular system (labored breathing, bradycardia,
hypotension) were shown to increase in severity if the dosage was repeated 24 hours later
(Zhang, 2002). A dosage of 45 mg/kg was shown to be well-tolerated in rats who
received treatment for 6 consecutive days, and also appeared neuroprotective at this dose
by
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Table 1 - Treatment groups and corresponding n values. Listed are the number of animals
that underwent successful surgeries and were included in the experiment.
3 Day

21 Day
Aβ (6)

Untreated

ET-1 (6)

Reverse (4)

Aβ/ET-1 (4)

ET-1 (6)
Aβ/ET-1 (6)

Chloroquine-Treated
(CQ)

CQ ET-1 (5)

CQ ET-1 (4)

CQ Aβ/ET-1 (5)

CQ Aβ/ET-1 (5)
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2.5 Immunohistochemistry
Series from each treatment group were processed simultaneously to reduce
variability between groups. Sections were washed in 0.1 M PBS (5 x 10 minutes each),
then quenched for 15 minutes in 1.5% hydrogen peroxide. Sections were washed in PBS
(3 x 5 minutes each), then blocked in 1.5% bovine serum albumin (BSA) (Serological
Research Institute, Richmond, USA) diluted in PBS with Triton-X (PBST) for 30
minutes. Sections were incubated with primary antibodies diluted in 1.5% BSA (PBST)
for 48 hours at 4°C on a shaker. Immunohistochemistry procedure was similar for: mouse
anti-rat OX-6 (1:1000, BD Biosciences, Mississauga, Canada), NeuN (1:1000, EMD
Millipore, Billerica, USA), GFAP (1:1000, EMD Millipore, Billerica, USA) GM3 (1:500,
Seikagaku Corporation, Tokyo, Japan), GM1 and GD1b (1:500, Ronald Schnaar, Johns
Hopkins University, USA); however Triton-X was not used for GM3, GM1 or GD1b
staining due to its membrane delocalizing effects (Lopez & Schnaar, 2009).
Sections were washed in PBS (5 x 5 minutes each) then incubated with HRPconjugated secondary antibodies diluted in 1.5% BSA (PBST) for 1 hour. HRPconjugated (anti-mouse IgG) (1:200, Vector Laboratories, Burlington, Canada) and antirabbit IgG secondary antibodies (1:200, Vector Laboratories, Burlington, Canada) were
used for the appropriate primary antibodies. Sections were washed in PBS (3 x 5 minutes
each) then incubated in Avidin-Biotinylated Complex (ABC) reagent (Vector
Laboratories, Burlington, Canada) for 1 hour. Sections were washed in PBS (3 x 5
minutes each) then developed in fresh 0.001% Diaminobenzidine (DAB) (Vector
Laboratories, Burlington, Canada) at 10 mg in 20 mL PBS with 300 µL 3% H202, Sigma
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for 5 minutes. Sections were washed in PBS (3 x 10 minutes each) then mounted onto
VWR microscope slides in 0.3% gelatin
2.6 Immunohistochemical Controls
Secondary controls using anti-mouse and anti-rabbit HRP-conjugated secondary
antibodies were performed as negative controls, and a typical section showed no nonspecific binding (Fig. 12a). Further, in order to confirm the detection of GM3 antibody, a
series of control immunohistochemical procedures were carried out. These included a
secondary control, in which the anti-GM3 antibody was left out of the primary incubation
(1.5% BSA only); a competitive co-incubation, in which 0.5 mg of excess GM3
ganglioside (Seikagaku Corporation, Tokyo, Japan) was co-incubated for the 48 hour
primary incubation with anti-GM3 primary antibody; and lastly the primary GM3
antibody was tested on an embryonic day 13.5 mouse brain as a positive control,
following the same immunohistochemical procedures once the fresh-frozen tissue was
thaw-mounted onto a microscope slide and post-fixed in PFA for 10 minutes.
2.7 Fluoro Jade B protocol
Sections were washed in PBS (6 x 10 minutes each) then mounted onto
microscope slides with 0.3% gelatin and allowed to dry overnight. Slides were placed in
1% sodium hydroxide in 80% ethanol for 5 minutes. Slides were then rehydrated in 95%
ethanol for 3 minutes; 70% ethanol for 3 minutes; 50% ethanol for 2 minutes, and finally
distilled water (3 x 1 minute each). Slides were then incubated in 0.06% potassium
permanganate (KMnO4) for 15 minutes on a shaker, in the dark. Slides were then washed
in distilled water (3 x 1 minute each), then placed in fresh 0.0004% Fluoro Jade B
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(Millipore, Billerica, USA) in 0.1% acetic acid for 20 minutes on a shaker in the dark.
Afterwards slides were washed in distilled water (3 x 1 minute each) then allowed to dry
in the fume hood before a xylene wash (1 minute) and coverslip with Depex.
2.8 Immunofluorescence
Free-floating sections were washed in PBS (3 x 10 minutes) then blocked in 1.5%
BSA for 1 hour at room temperature. Sections were incubated with GM3 [1:500] and
either NeuN (1:1000, Millipore, Billerica, USA), GFAP (1:1000, Millipore, Billerica,
USA) or IBA-1 for activated microglia/macrophages (1:1000, Santa Cruz Biotechnology
Inc., Santa Cruz, USA) in 1.5% BSA for 48 hours at 4° C.
Sections were washed in PBS (3 x 10 minutes each) then incubated with FITCconjugated anti-mouse IgG (1:300, Santa Cruz Biotechnology Inc., Santa Cruz, USA) and
TR-conjugated anti-rabbit IgG (1:300, Santa Cruz Biotechnology Inc., Santa Cruz, USA)
for 1 hour at room temperature in the dark. Sections were washed in PBS (3 x 10
minutes) and mounted onto microscope glass slides in 0.3% gelatin and allowed to dry
overnight before a xylene wash (1 minute) and coverslipped with Depex.
2.9 Imaging
Images were taken on a Leica DC300 (Leica Microsystems, Concord, Canada)
camera microscope. Analysis and quantification was carried out using ImageJ (Wayne
Rasband, National Institute of Health, Bethesda, USA) by one observer who was blinded
to the treatment group.
The following parameters were used for analysis:
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Expression volume
Expression volume of OX-6 (“Inflammation Volume”) and GM3 (“GM3
Expression Volume”) in the striatum ipsilateral to the stroke were calculated as correlates
of infarct volume.
The striatum was defined based on the following bordering landmarks: superiorly
and laterally by the corpus callosum, medially by the lateral ventricle, and inferiorly by
the anterior commissure. An entire series (approximately 24 sections) was stained from
each brain for OX-6 and GM3 respectively, from -1.2 mm to 3.8 mm relative to Bregma.
After sections had been mounted and cover-slipped they were scanned (Epson Scanner)
and analyzed in ImageJ (NIH, Maryland, USA). Images were inverted to improve
contrast, with a threshold for a positive stain set at a mean intensity of 75 out of 255.
Expression volume was normalized to the ipsilateral (ischemic) and contralateral (nonischemic) hemispheres to account for any contribution of hemispheric swelling (Lin et
al., 1993), and was calculated using the equation:
Volume = (Σ(Infarct Surface Area x (Contralateral/Ipsilateral Hemisphere))) x Length
Length was defined as the number of sections on which the infarct was measured minus 1
(n-1), multiplied by the thickness of the sections (35 µm) and the distance between
sections (280 µm).
Optical Density
Optical density measurements of OX-6 and GM3 staining were taken as correlates
of the number of microglia and concentration of GM3. Arbitrary units were assigned to
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compare optical density. Different treatment groups were always processed
simultaneously with the same solutions in order to reduce variation in DAB staining.
Density values of OX-6 and GM3 staining were normalized as follows: the mean
intensity values of the measurements used for infarct volume were averaged for each
brain and normalized with the values from the appropriate comparison group, with the
highest value assigned 100 and the lowest value assigned 0. Comparisons of optical
density show the average value per group, and were only carried for groups processed
simultaneously.
Neuronal Quantification (%NeuN Expression)
Expression of the neuron-specific protein NeuN in the ipsilateral striatum was
quantified as the average ratio of ipsilateral/contralateral striatal NeuN positive cells from
three sections per brain. The average for each brain was taken from three slices at the
approximate Bregma levels 0.6 to 0.8 mm; 0 to -1.2; and -1.4 to -1.8 mm
anterior/posterior. Images were taken at a 1.5x magnification, and NeuN positive cells
were counted using the Analyze Particles tool in ImageJ. This approach proved effective
as differences in Bregma level affect striatal area, however the values were normalized to
an internal control (contralateral striatum).
Fluoro Jade B Cell Counts
Fluoro Jade B (FJB), a marker for cellular degeneration (Schmued and Hopkins,
2000; Damjanac et al., 2006) cell counts were counted manually as the average number
of FJB-positive cells in the ipsilateral striatum from three brain slices. No FJB positive
cells were detected in the contralateral striatum. The average for each brain was taken
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from three slices at the approximate Bregma levels 0.6 - 0.8 mm; 0 – (-1.2); and (-1.4) –
(-1.8) mm anterior/posterior, counted under 16x magnification.
Quantification of Complex Gangliosde Expression (%GM1/GD1b Expression)
The mean intensity value from a 0.33 mm2 area was measured from the infarct in the
ipsilateral striatum and compared against the corresponding area in the contralateral
striatum as the ratio of ipsilateral/contralateral staining intensity, expressed as the percent
difference (reduction) from the expected difference of 0. Values are the average of three
measurements per brain.
2.10 Determination of Aβ Aggregation State
To confirm that Aβ was not aggregated upon injection, Aβ25-35 underwent matrixassisted laser desorption/ionization (MALDI) mass spectrometric analysis to determine
aggregation state of the Aβ peptide under similar conditions to surgery. Aβ25-35 is
typically aggregated at room temperature for several days (Kreutz et al., 2011). Aβ25-35 (5
mmol) was kept on dry ice right up until it was spotted onto a 41 mm x 41 mm stainless
steel MALDI plate (AB Sciex, Foster City, USA), The plate was dried in a vaccuum for
20 minutes then placed in a humidor at ambient temperature at 80% relative humidity for
40 minutes. The plate was then sprayed manually with α-cyano-4-hydroxycinnamic acid
(CHCA) matrix using an airbrush. MS/MS analysis was done on an Applied Biosystems
4800 MALDI TOF/TOF.
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2.11 Data Analysis
Statistical analysis was performed using Prism 4.0 (GraphPad) for Windows.
Two-tailed Student’s t-tests were used for two-group comparisons, while comparisons of
multiple groups were carried out using a randomized one-way analysis of variance
(ANOVA). Significance between groups was determined by Tukey’s post-test. Linear
regression analysis was performed using Excel (Microsoft Corporation) un-blinded, as
animal ID’s were used to pair appropriate measures. Numerical data are presented as
mean + SEM. A p-value of < 0.05 was considered statistically significant.
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Section 3

RESULTS
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3.1 Effects of Aβ Toxicity and Stroke
3.1.1 Aggregation State of Aβ25-35
Soluble Aβ25-35 has demonstrated neurotoxicity both in vitro and in vivo as well as
the ability to aggregate (Yankner et al., 1990; Pike et al., 1995; Tsuruma et al., 2010;
Kowall et al., 1992), and compared to the full-length Aβ peptides allows for greater
diffusion throughout the ventricles to induce generalized Aβ toxicity in our model
(Whitehead et al., 2005a; 2007a; Cheng et al., 2006). There are conflicting results relating
the aggregation state of Aβ to its neurotoxicity (Kruetz et al., 2011; Tam and Pasternak,
2012; Benilova et al., 2012), however, soluble Aβ species, and not amyloid plaques, have
shown to correlate with synaptic loss (Benilova et al., 2012; Tam and Pasternak, 2012),
further supporting the use of soluble Aβ to model the neurodegenerative mechanisms in
the brain at risk for developing AD.
Preparation of the Aβ25-35 sample for MALDI analysis took approximately an
hour, during which time the spotted Aβ25-35 was at room temperature. Thus it was
exposed to room temperature for significantly longer than it would be during surgical
procedure and injection (approximately 25 minutes). Aβ25-35 gave a strong signal at
1082.78 m/z (mass-to-charge ratio, equivalent mass units) (Fig. 4), which is the Na+
adduct of Aβ25-35: in order for detection to occur, analytes must be desorbed from the
sample and ionized in order to traverse the vacuum, which is mediated by the matrix. To
illustrate this point, there is no peak corresponding to the molecular mass of the Aβ25-35
molecule (1062 m/z). There were no Aβ aggregates or oligomers detected, as MALDI
allows for the detection of higher mass proteins and protein aggregates (Caprioli et al.,
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Figure 4 - MALDI analysis of Aβ aggregation state. Aβ25-35 underwent MALDI mass
spectral analysis on an Applied Biosystems 4800 MALDI TOF/TOF with CHCA matrix.
The strong signal peak at 1082.78 m/z represents the Na+ adduct of Aβ25-35. There were
no masses detected above 1500 m/z units, indicating there were no Aβ aggregates or
oligomers in the sample.
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1997), suggesting there is little to no aggregation of Aβ25-35 upon exposure to room
temperature for 60 minutes.
3.1.2 Aβ & Reverse Animals Lack Striatal Pathology
Aβ and Reverse animals demonstrated no OX-6 expression (Fig. 5a,e), cellular
degeneration (Fig. 5b,f) neuronal loss (Fig. 5c,g) or GM3 accumulation (Fig. 5d,h) in the
striatum at 21 days after bilateral i.c.v. injections. Since the stroke-induced pathology is
restricted to the striatum, Aβ and Reverse groups are excluded from all subsequent
figures and analyses.
3.1.3 OX-6 Expression: Neuroinflammatory Response
The activation, proliferation and migration of microglia is a critical component of
both the acute and chronic neuroinflammatory response (Stoll et al., 1998). Series were
stained with the microglial marker OX-6 to examine microglial reactivity (Vinet et al.,
2012) and serve as a correlate of neuroinflammation. At 3 days after surgery, ET-1 and
Aβ/ET-1 animals were not significantly different based on the number of microglial cells
identified by OX-6 expression volume – normalized for hemispheric swelling - or OX-6
staining intensity – normalized between groups - in the ipsilateral striatum (p > 0.05, n =
6 each, Fig. 6e,j). Microglia were present throughout the infarct region at a similar
concentration and exhibited a rounded morphology (Fig. 6g,i).
At 21 days after surgery, OX-6 immunostaining revealed the inflammatory
response was still active at 21 days, as both ET-1 and Aβ/ET-1 rats showed a significant
increase in OX-6 expression volume from 3 days (225% and 709%, respectively, p <
0.05, Fig. 7e). Both groups displayed highly ramified microglia that were densely
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Figure 5 - Striatal pathology is absent in Aβ and Reverse animals at 21 days after surgery.
Photomicrographs of brain sections from an Aβ (n = 6) and Reverse (n = 4) rat
corresponding to the area of the infarct demonstrate no observable striatal pathology,
assessed by (a,e) OX-6 expression for ramified microglia; (b,f) Fluoro Jade B detection
for cellular degeneration; (c,g) neuronal protein marker NeuN expression for neuronal
loss, and (d,h) pathological expression of GM3. Sections are taken from the same animal
per group.
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Figure 6 - Aβ toxicity had no effect on OX-6 expression at 3 days after surgery. (a-d)
Photomicrographs of ramified microglia, identified by OX-6 staining in the striatum of
ET-1 (n = 6) and Aβ/ET-1 (n = 4) animals at 3 days after surgery. Areas boxed in lower
power (1.5x) photomicrographs (a-d) are shown in higher power (10x) in panels (f-i) and
demonstrate similar microglial morphology at 3 days between groups, with expression
limited to the ipsilateral striatum. (e) OX-6 expression volume and (j) OX-6 staining
intensity quantified throughout the ipsilateral striatum at 3 days (T-test: Volume, t8=
.6019, p = 0.56; Optical Density, t8 = 1.286, p = 0.23).
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Figure 7 – OX-6 expression at 21 days after surgery. Photomicrographs of ramified
microglia immunostained by OX-6 in the striatum of ET-1 (n = 6) and Aβ/ET-1 (n = 6)
animals at 21 days after surgery. Areas boxed in lower power (1.5x) photomicrographs
(a-d) are shown in higher power (10x) in panels (f-i) and demonstrate highly ramified
microglia concentrated in the infarct core in the ipsilateral striatum. (e) OX-6 expression
volume and (j) OX-6 staining intensity quantified throughout the ipsilateral striatum at 21
days (T-test: Volume, t10 = 1.458, p = 0.18; Optical Density, T-test: t10 = 1.517, p = 0.16).
Percentages and * indicate % change and significance from 3 day animals (T-test: ET-1,
t10 = 2.513, p < 0.05; Aβ/ET-1, t8 = 1.817, p < 0.05). *p < 0.05.
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concentrated in the infarct (Fig. 7g,i). There was no significant difference in OX-6
expression volume or staining intensity between groups at 21 days after surgery (p >
0.05, Fig. 7e,j), though Aβ/ET-1 rats showed approximately a two-fold increase in OX-6
expression volume compared to ET-1 rats.
3.1.4 Fluoro Jade B: Cellular Degeneration
Fluoro Jade B (FJB) is a polyanionic molecule that binds polyamines, which are
compounds that accumulate in degenerating cells regardless of cause or type of cell death
(Schmued and Hopkins, 2000; Damjanac et al., 2006). Therefore FJB is ideal for
assessing stroke-induced cell death, which includes both necrotic and apoptotic pathways
(Gabryel et al., 2012).
At 3 days, ET-1 and Aβ/ET-1 exhibited obvious cellular degeneration as FJBpositive cells were extensively – and exclusively - distributed throughout the infarct core
(Fig. 8a,b). Quantifying FJB expression showed there was no significant difference in the
total number of FJB positive cells at 3 days after surgery (p > 0.05, Fig. 8c), indicating
there was no acute effect of Aβ on stroke-induced cell death.
At 21 days after surgery, both ET-1 and Aβ/ET-1 rats showed a significant
reduction in the number of FJB positive cells in the ipsilateral striatum (p < 0.001, p <
0.05, respectively) as they were largely absent in the necrotic core and concentrated along
the periphery of the infarct (Fig. 8d,e). Aβ/ET-1 rats had 33% more FJB positive cells at
21 days compared to ET-1 rats, and while there was no significant difference in FJB cell
counts between ET-1 and Aβ/ET-1 rats at 21 days after surgery (p > 0.05, Fig. 8f),
Aβ/ET-1 rats showed a much smaller – though still significant - decrease from 3 days.
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Figure 8 – Cellular degeneration at 3 and 21 days after surgery in the infarct assessed by
Fluoro Jade B. (a,b) Photomicrographs (16x) of degenerating cells in the ipsilateral
striatum identified by Fluoro Jade B (FJB) at 3 and 21 (d,e) days after surgery in ET-1
and Aβ/ET-1 animals. FJB positive cells indicate extensive cellular degeneration in the
infarct core at 3 days after surgery, and at the border of the infarct at 21 days after
surgery. (c) Counts of FJB positive cells at 3 and (f) 21 days after surgery in ET-1 and
Aβ/ET-1 animals (n = 6, n = 6, n = 4, n = 6 respectively). There were no significant
differences between groups at 3 or 21 days in cell counts (T-test: 3 day, t8 = 1.176, p =
0.27; 21 day, t10 = 1.735, p = 0.11). Percentages are 21 day values as a percentage of 3
day values, and * indicate significance from 3 day animals (T-test: ET-1, t10 = 5.772, p <
0.001; Aβ/ET-1, t8 = 2.309, p < 0.05). Values are averaged from 3 sections per brain. *p
< 0.05, ***p < 0.001.
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These data suggest that in the absence of Aβ toxicity, endogenous repair mechanisms are
more effective at preventing progressive cellular loss following ischemic stroke.
3.1.5 NeuN - Neuronal Survival
To complement the FJB data indicating robust cellular degeneration, sections
were stained with the neuronal marker NeuN to provide an estimate of neuronal loss in
the ipsilateral striatum. The number of neurons immunoreactive for NeuN in the
ipsilateral striatum was expressed as a ratio of those in the contralateral striatum,
providing an internal control that allowed for more accurate comparisons.
At 3 days after surgery, there was no significant difference in NeuN expression
between ET-1 and Aβ/ET-1 animals (p > 0.05, Fig. 9e), however both groups showed
substantial neuronal loss in the ipsilateral striatum, losing roughly 35% and 40% of NeuN
positive neurons, respectively (Fig. 9b,d). The infarct core wasn’t clearly defined yet at 3
days, however, as NeuN-positive cells were still present throughout the core of the infarct
(Fig. 9g,i).
From 3 to 21 days after surgery, both ET-1 and Aβ/ET-1 rats showed nonsignificant progressive neuronal loss, losing an additional 7.2% and 15.6% of NeuN
positive neurons, respectively (p > 0.05). Aβ/ET-1 rats showed significantly greater
neuronal loss at 21 days compared to ET-1 rats, with only 45% of NeuN positive neurons
remaining compared to 58% in ET-1 rats (p < 0.05, Fig. 10e). Necrosis of the core is
likely to have contributed to the progressive neuronal loss, as NeuN positive cells are
almost completely absent from the core of the infarct at 21 days after surgery (Fig. 10g,i),
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Figure 9 – Expression of neuronal protein NeuN at 3 days after surgery. (a-d)
Photomicrographs of neurons identified by NeuN in the striatum of ET-1 and Aβ/ET-1
animals at 3 days after surgery. Areas boxed in lower power (1.5x) photomicrographs (ad) are shown in higher power (16x) in panels (f-i), demonstrating decreased NeuN
expression in the infarct. (e) Counts of neurons in the ipsilateral striatum identified by
NeuN in ET-1 (n = 6) and Aβ/ET-1 (n = 4) animals, expressed as a ratio of NeuN
expression in the contralateral striatum (T-test: t8 = 0.48, p = .64). Values are averaged
from 3 sections per brain.
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Figure 10 – Aβ/ET-1 showed progressive neuronal loss at 21 days after surgery. (a-d)
Photomicrographs of neurons identified by NeuN in the striatum of ET-1 and Aβ/ET-1
animals at 21 days after surgery. Areas boxed in lower power (1.5x) photomicrographs
(a-d) are shown in higher power (16x) in panels (f-i), demonstrating absence of NeuN
expression in the infarct. (e) Counts of neurons in the ipsilateral striatum identified by
NeuN in ET-1 (n = 6) and Aβ/ET-1 (n = 6) animals, expressed as a ratio of NeuN
expression in the contralateral striatum (T-test: t10 = 2.838, p < 0.05). Percentages
indicate change from corresponding 3 day animals (T-test: ET-1, t10 = 1.223, p = 0.25;
Aβ/ET-1, t8 = 2.23, p = 0.056). Values are averaged from 3 sections per brain. *p < 0.05.
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but expansion of the infarct into the penumbra is also evident from 3 (Fig. 9b,d) to 21
(Fig. 10b,d) 21 days after surgery. Once again, in the absence of Aβ toxicity there appear
to be endogenous mechanisms that promote repair or prevent progressive cell loss after
the initial acute ischemic event, as Aβ toxicity leads to progressive cellular and neuronal
loss.
3.1.6 Pathological Ganglioside Expression: GM3 Accumulation
The effect of striatal stroke - alone and in combination with Aβ toxicity - on
pathological ganglioside expression was assessed by immunostaining with an anti-GM3
antibody, as GM3 has been shown to accumulate following MCAO in the infarct (Kwak
et al., 2005; Whitehead et al., 2011). GM3 was detected at 3 days in ET-1 and Aβ/ET-1
animals, though its expression was limited to the infarct (Fig. 11b,d), as it was likely
below detection threshold throughout the rest of the brain. GM3 positive cells were
present throughout the infarct (Fig. 11g,i), with many exhibiting a neuronal morphology
(Fig. 11k,l). At 3 days after surgery, there was no significant difference between ET-1
rats and Aβ/ET-1 rats in GM3 expression volume (p > 0.05, Fig. 11e) or staining intensity
(p > 0.05, Fig. 11j).
At 21 days, GM3 expression volume (Fig. 12e) – normalized for hemispheric
swelling - and staining intensity (Fig. 12j) – normalized between groups - was
significantly greater in Aβ/ET-1 animals compared to ET-1 animals (p < 0.05). There was
a significant reduction in GM3 expression volume in ET-1 animals from 3 to 21 days (p <
0.05), while Aβ/ET-1 animals showed a non-significant increase in GM3 expression
volume (p > 0.05). GM3 staining appeared primarily extracellular in the infarct core,
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Figure 11 – GM3 expression in the infarct at 3 days after surgery. (a-d) Photomicrographs
of GM3 immunostaining in the ipsilateral striatum of ET-1 and Aβ/ET-1 animals at 3
days after surgery. Areas boxed in lower power (1.5x) photomicrographs (a-d) are shown
in higher power (16x) in panels (f-i), and again in panels (40x) (k,l) demonstrating the
neuronal morphology of GM3 positive cells. (e) GM3 expression volume and (j) GM3
staining intensity quantified throughout the ipsilateral striatum at 3 days in ET-1 (n = 6)
and Aβ/ET-1 (n = 4) animals (T-test: Volume, t8 = 1.034, p = 0.33; Optical Density, t8 =
0.07, p = 0.95).
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Figure 12 - Aβ toxicity enhanced stroke-induced expression of GM3 at 21 days after
surgery. (a-d) Photomicrographs of GM3 expression of GM3 immunostaining in the
ipsilateral striatum of ET-1 and Aβ/ET-1 animals at 21 days after surgery. Areas boxed in
lower power (1.5x) photomicrographs (a-d) are shown in higher power (16x) in panels (fi), demonstrating the predominantly extracellular expression of GM3. (e) GM3
expression volume and (j) GM3 staining intensity quantified throughout the ipsilateral
striatum at 21 days in ET-1 (n = 6) and Aβ/ET-1 (n = 6) animals (T-test: Volume, t10 =
2.234, p < 0.05; Optical Density, t10 = 2.987, p < 0.05). Percentages are 21 day values as
a percentage of 3 day values, and * indicates significance from 3 day animals (T-test: ET1, t10 = 2.804, p < 0.05; Aβ/ET-1, t8 = 1.163, p = 0.28). *p < 0.05.
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with a cellular staining pattern in the periphery of the infarct region along the border (Fig.
12g,i).
3.1.7 GM1 and GD1b: Expression of complex gangliosides
Sections were immunostained for GM1 and GD1b to examine the effect of stroke
on complex ganglioside expression in the context of GM3 accumulation, in order to
determine if GM3 accumulation does in fact represent a protective response and
increased ganglioside biosynthesis as proposed by Kwak et al. (2005). To quantify
changes in the expression of GM1 and GD1b, which are ubiquitously expressed
throughout the brain, and control for variation in DAB staining, staining intensity in the
infarct was evaluated relative to the contralateral striatum as a way to detect differences
in expression level by immunohistochemistry. As both GM1 and GD1b staining intensity
was reduced in the infarct relative to the contralateral striatum, values were expressed as
the % reduction relative to the contralateral striatum, and analyzed between groups and
against the expected difference of 0.
At 3 days after surgery, GM1 staining intensity was significantly reduced in the
infarct compared to the contralateral striatum for both ET-1 and Aβ/ET-1 rats (Fig. 13b,d,
p < 0.01) however there was no significant difference between groups (p > 0.05, Fig.
13e). GM1 expression was diffuse throughout the striatum, and also appeared to a lesser
extent in the corpus callosum (Fig. 13a-d). At 21 days, GM1 staining intensity was
significantly reduced in the infarct for both ET-1 and Aβ/ET-1 groups (Fig. 13g,i, p <
0.05), but there was no significant difference between groups (Fig. 13j, p > 0.05) and

	
  69	
  

	
  

	
  

	
  

	
  

Figure 13 – GM1 expression at 3 and 21 days after surgery in the infarct. (a-d)
Photomicrographs of GM1 immunostaining in the striatum of ET-1 and Aβ/ET-1 animals
at 3 and 21 (f-i) days after surgery (1.5x). GM1 expression is diffuse throughout the
striatum, yet decreased in the infarct. Quantification of reduced GM1 expression in ET-1
and Aβ/ET-1 animals at 3 (e) and 21 (j) days after surgery (n = 6, n = 4, n = 6, n = 6
respectively) expressed as the reduction in GM1 staining intensity in the infarct relative
to the contralateral striatum, analyzed against the expected difference of 0 (T-test: 3d ET1, t5 = 8.61, p < 0.01; 3d Aβ/ET-1, t3 = 7.171, p < 0.01; 21 d ET-1, t5 = 7.165, p < 0.05;
21d Aβ/ET-1, t5 = 2.752, p < 0.05). There was no significant difference between groups
at 3 or 21 days (T-test: 3d, t8 = 2.011, p = 0.09; 21d, t10 = 0.125, p = 0.9). Values are the
average of 3 measurements per brain. *p < 0.05, **p < 0.01.
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there was no significant difference from 3 days for either group (p > 0.05). GM1
appeared highly concentrated around the infarct at 21 days (Fig. 13g,i).
At 3 days after surgery, GD1b staining intensity in the infarct was significantly
reduced compared to the contralateral striatum in both ET-1 and Aβ/ET-1 rats (Fig.
14b,d, p < 0.05, p < 0.01 respectively) however there was no significant difference
between groups (Fig. 14e, p > 0.05). GD1b staining appeared diffuse throughout the
striatum and the corpus callosum at 3 days after surgery (Fig. 14a-d). At 21 days after
surgery, GD1b staining intensity was significantly decreased in both ET-1 and Aβ/ET-1
rats compared to the contralateral striatum (Fig. 14j, p < 0.05). There was no significant
difference between groups in reduction of GD1b staining intensity (Fig. 14j, p > 0.05),
and there was no significant difference between 3 and 21 days after surgery for ET-1 or
Aβ/ET-1 rats (p > 0.05). GD1b expression was highly concentrated around the infarct at
21 days after surgery, and again was diffuse throughout the striatum and present in the
corpus callosum (Fig. 14g,i)
3.1.8 GM3 Immunohistochemical Controls
To confirm detection of GM3 by immunohistochemistry, several standard control
protocols were run on sections from an Aβ/ET-1 21 day brain to assess the sensitivity and
specificity of the anti-GM3 primary antibody. Upon omitting the anti-GM3 primary
antibody (Fig. 15a,e) or co-incubating with excess GM3 (Fig. 15b,f), there was no
positive stain detected in the ipsilateral striatum. Under standard IHC protocol, GM3 is

	
  71	
  

	
  

	
  

	
  

	
  

Figure 14 – GD1b expression at 3 and 21 days after surgery in the infarct. (a-d)
Photomicrographs of GD1b immunostaining in the striatum of ET-1 and Aβ/ET-1
animals at 3 and 21 (f-i) days after surgery (1.5x). GD1b expression is diffuse throughout
the striatum, yet decreased in the infarct. Quantification of reduced GD1b expression in
ET-1 and Aβ/ET-1 animals at 3 (e) and 21 (j) days after surgery (n = 6, n = 4, n = 6, n = 6
respectively) expressed as the reduction in GD1b staining intensity in the infarct relative
to the contralateral striatum, analyzed against the expected difference of 0 (T-test: 3d ET1, t5 = 3.591, p < 0.05; 3d Aβ/ET-1, t3 = 8.964, p < 0.01; 21d ET-1, t5 = 3.933, p < 0.05;
21d Aβ/ET-1, t5 = 6.584, p < 0.05). There was no significant difference between groups
at 3 or 21 days (T-test: 3d, t8 = 0.8554, p = 0.43; 21d, t10 = 1.503, p = 0.21). Values are
the average of 3 measurements per brain. *p < 0.05, **p < 0.01.
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Figure 15 - Immunohistochemical controls for detection of GM3. Photomicrographs of
immunohistochemical controls in adjacent brain sections from a 21 day Aβ/ET-1 rat to
confirm detection of GM3: (a) negative control with primary anti-GM3 antibody omitted
from primary incubation, (b) preabsorption of primary anti-GM3 antibody with excess
GM3, (c) standard immunostaining of GM3 in the infarct, and (d) positive control with
primary anti-GM3 antibody tested in a day 13.5 embryonic mouse brain. Areas boxed in
lower power (1.5x) photomicrographs (a-d) are shown in higher power (15x) in panels eh.
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detected in the infarct (Fig. 15c,g). As a positive control embryonic mouse brain was
stained with the anti-GM3 primary antibody, as GM3 is expressed in the developing CNS
(Nakatsuji and Miller, 2001) and demonstrated a positive stain (Fig. 15d,h).
3.1.9 Dual-labeled immunofluorescence
Immunofluorescence was performed on adjacent sections from a 21 day Aβ/ET-1
brain to demonstrate the cellular expression profile of GM3, and to determine whether
GM3 expression is associated with a positive FJB signal, indicating cellular degeneration.
GM3 co-localizes extensively with neurons in the periphery of the infarct (Fig. 16c). At
21 days, GFAP-positive astrocytes surround the infarct at the border of the infarcted
tissue and show no co-localization with GM3 (Fig.16f). IbA-1 positive microglia are
present throughout the infarct, and roughly half appear to co-localize with GM3 (Fig.
16i). Lastly, the majority of FJB positive cells within the periphery of the infarct appear
to co-localize with GM3 (Fig. 16l).
3.2 Effects of Chloroquine
3.2.1 OX-6 Expression in Chloroquine Animals
At 3 days after surgery, CQ ET-1 and CQ Aβ/ET-1 rats were not significantly
different based on the number of microglia identified by OX-6 expression volume or OX6 staining intensity in the ipsilateral striatum (Fig. 17e,j, p > 0.05). Microglia were
present throughout the infarct region at a similar density and exhibited a rounded
morphology (Fig. 17g,i). CQ treatment had no effect on OX-6 expression volume at 3
days, as there were no significant differences between untreated and treated groups (Fig.
19a, p > 0.05).
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Figure 16 – Immunofluorescent dual labeling with GM3. Photomicrographs (16x) of
GM3 expression in the striatum from a 21d Aβ/ET-1 animal dual labeled with (a-c)
neuronal protein NeuN in the periphery of the infarct, (d-f) astrogliosis marker GFAP at
the border of the infarcted tissue, (g-i) macrophage/microglial protein IbA-1 in the core
of the infarct and (i-l) Fluoro Jade B, a marker of cellular degeneration at the periphery of
the infarct. GM3 co-localizes well with NeuN and FJB, with some co-localization with
IbA-1.
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Figure 17 – OX-6 expression at 3 days after surgery in Chloroquine-treated animals. (a-d)
Photomicrographs of ramified microglia identified by OX-6 staining in the striatum of
CQ ET-1 (n = 5) and CQ Aβ/ET-1 (n = 5) animals at 3 days after surgery. Areas boxed in
lower power (1.5x) photomicrographs (a-d) are shown in higher power (10x) in panels (fi) and demonstrate similar microglial morphology between groups, with expression
limited to the ipsilateral striatum. (e) OX-6 expression volume and (j) OX-6 staining
intensity quantified throughout the ipsilateral striatum at 3 days (T-test: Volume, t8 =
1.166, p = 0.28; Optical Density, t8 = 1.053, p = 0.32).
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From 3 to 21 days after surgery, OX-6 expression volume in CQ ET-1 rats had

decreased by almost 50%, while in CQ Aβ/ET-1 rats OX-6 expression volume had
increased by almost 200%; compared to the 225% and 709% increases in ET-1 and
Aβ/ET-1 rats from 3 to 21 days. While CQ effectively reduced the progressive increase in
OX-6 expression volume, results still implicate Aβ toxicity in aggravating stroke induced
OX-6 expression over time. CQ ET-1 and CQ Aβ/ET-1 rats were not, however,
significantly different in OX-6 expression volume (Fig. 18e, p > 0.05) or OX-6 staining
intensity (Fig. 18j, p > 0.05) at 21 days after surgery. Microglia appeared ramified and
highly concentrated in the infarct region at 21 days (Fig. 18g,i). CQ treatment resulted in
non-significant reductions in OX-6 expression volume at 21 days compared to untreated
animals for both CQ ET-1 and CQ Aβ/ET-1 animals (29.9% and 22.1% of untreated OX6 expression volumes, respectively, Fig. 19b, p > 0.05).
3.2.2 Fluoro Jade B in Cholorquine-Treated Animals
At 3 days after surgery, FJB positive cells were present throughout the core of the
infarct in both CQ ET-1 and CQ Aβ/ET-1 rats (Fig. 20a,b) and FJB cell counts in the
ipsilateral striatum showed no significant difference between CQ-treated groups (Fig.
20c, p > 0.05). CQ treatment led to non-significant reductions in the number of FJB cells
at 3 days after surgery in CQ ET-1 and CQ Aβ/ET-1 rats compared to the corresponding
untreated groups (76.2% and 54% of untreated FJB cell counts, respectively, Fig. 21a, p
> 0.05). From 3 to 21 days after surgery, both CQ ET-1 and CQ Aβ/ET-1 rats showed
non-significant reductions in FJB cell counts (32.2% and 61.1% of 3 day counts,
respectively, p > 0.05). At 21 days, FJB cells were concentrated mostly in the perimeter
of the infarct, with few FJB-positive cells present in the core of the infarct (Fig. 20d,e).
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Figure 18 – OX-6 Expression at 21 days after surgery in Chloroquine-treated animals. (ad) Photomicrographs of ramified microglia, identified by OX-6 staining in the striatum of
CQ ET-1 (n = 4) and CQ Aβ/ET-1 (n = 5) animals at 21 days after surgery. Areas boxed
in lower power (1.5x) photomicrographs (a-d) are shown in higher power (10x) in panels
(f-i) and demonstrate highly ramified microglia concentrated in the infarct core in the
ipsilateral striatum. (e) OX-6 expression volume and (j) OX-6 staining intensity
quantified throughout the ipsilateral striatum at 21 days (T-test: Volume, t7 = 0.6512, p =
0.54; Optical Density, t7 = 0.7793, p = 0.46). Percentages indicate % change from
corresponding 3 day animals (T-test: CQ ET-1, t7 = 0.8929, p = 0.4; CQ Aβ/ET-1, t8 =
0.8825, p = 0.4).

	
  78	
  

	
  

	
  

	
  

	
  

Figure 19 – Effect of Chloroquine on OX-6 expression volume at 3 and 21 days. OX-6
expression volumes at 3 (a) and 21 (b) days after surgery in untreated (white bars) and
CQ-treated (shaded bars) ET-1 and Aβ/ET-1 animals (3d n = 6, n = 5, n = 4, n = 5; 21d n
= 6, n = 4, n = 6, n = 5 respectively). There was no significant effect of CQ at 3 or 21
days after surgery (ANOVA: 3d, F3,16 = 0.6684, p = 0.58; 21d, F3,17 = 2.946, p = 0.06).
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Figure 20 - Cellular degeneration at 3 and 21 days after surgery in Chloroquine-treated
animals assessed by Fluoro Jade B. (a,b) Photomicrographs (16x) of degenerating cells in
the ipsilateral striatum identified by Fluoro Jade B (FJB) at 3 and 21 (d,e) days after
surgery in CQ ET-1 and CQ Aβ/ET-1 animals. FJB positive cells indicate cellular
degeneration in the infarct core at 3 days after surgery, and at the border of the infarct at
21 days after surgery. (c) Counts of FJB positive cells at 3 and (f) 21 days after surgery in
CQ ET-1 and CQ Aβ/ET-1 animals (n = 5, n = 5, n = 4, n = 5, respectively). There were
no significant differences between groups at 3 or 21 days in cell counts (T-test: 3d, t8 =
1.286, p = 0.23; 21d, t7 = 0.2873, p = 0.78). Percentages are 21 day values as a percentage
of 3 day values, which show no significant difference across time points (T-test: CQ ET1, t7 = 2.052, p = 0.08; CQ Aβ/ET-1, t8 = 1.268, p = 0.24). Values are the average of 3
sections per brain.
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Figure 21 – Effect of Chloroquine on Fluoro Jade B cell counts at 3 and 21 days. Fluoro
Jade B (FJB) cell counts at 3 (a) and 21 (b) days after surgery in untreated (white bars)
and CQ-treated (shaded bars) ET-1 and Aβ/ET-1 animals (3d n = 6, n = 5, n = 4, n = 5;
21d n = 6, n = 4, n = 6, n = 5, respectively). There was no significant effect of CQ at 3
days, however there was a significant effect of CQ at 21 days (ANOVA: 3d, F3,16 =
2.734, p = 0.08; 21d F3,17 = 5.199, p < 0.01; Tukey’s p < 0.05). *p < 0.05.
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CQ ET-1 and CQ Aβ/ET-1 groups were not significantly different at 21 days in FJBpositive cells in the striatum (Fig. 20f). CQ treatment led to a significant reduction in the
number of FJB positive cells at 21 days in CQ Aβ/ET-1 rats (51% of Aβ/ET-1 counts, p <
0.05) and a non-significant decrease in CQ ET-1 rats (61.5% of ET-1 rats, p > 0.05) (Fig.
21b).
3.2.3 NeuN Expression in Chloroquine-Treated Animals
At 3 days after surgery there was no significant difference between CQ ET-1 and
CQ Aβ/ET-1 animals in neuronal loss in the ipsilateral striatum (losing roughly 36% and
19%, respectively, Fig. 22e, p > 0.05). The infarct region was poorly defined at 3 days
(Fig 22b,d), with NeuN-positive cells present throughout the core of the infarct (Fig.
22g,i). CQ treatment had no significant effect on neuronal loss at 3 days compared to the
corresponding untreated groups (Fig. 24a, p > 0.05), suggesting CQ was unable to
prevent the substantial acute neuronal loss following stroke.
There was no significant difference in NeuN expression between 3 and 21 days
for CQ ET-1- and CQ Aβ/ET-1 groups (p > 0.05), despite an apparent increase in NeuN
expression in CQ ET-1 rats at 21 days after surgery. Thus while CQ was unable to
prevent the acute neuronal loss it effectively prevented expansion of the infarct at 21 days
after surgery, as there was some progressive neuronal loss within the infarct region which
was well defined at 21 days with very few NeuN positive cells in the core of the infarct
(Fig. 23g,i). At 21 days after surgery, CQ ET-1 and CQ Aβ/ET-1 groups were not
significantly different in neuronal loss (Fig. 23e, p > 0.05). CQ treatment significantly
improved neuronal survival at 21 days, as CQ ET-1 and CQ Aβ/ET-1 showed
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Figure 22 – Expression of neuronal protein NeuN at 3 days after surgery in Chloroquinetreated animals. Photomicrographs of neurons identified by NeuN in the striatum of CQ
ET-1 and CQ Aβ/ET-1 animals at 3 days after surgery. Areas boxed in lower power
(1.5x) photomicrographs (a-d) are shown in higher power (10x) in panels (f-i),
demonstrating decreased NeuN expression in the infarct. (e) Counts of neurons in the
ipsilateral striatum identified by NeuN in CQ ET-1 (n = 5) and CQ Aβ/ET-1 (n = 5)
animals, expressed as a ratio of the contralateral striatum (T-test: t8 = 1.656, p = 0.14).
Values are averaged from 3 sections per brain.
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Figure 23 – Neuronal survival at 21 days in Chloroquine-treated animals. (a-d)
Photomicrographs of neurons identified by NeuN in the striatum of CQ ET-1 and CQ
Aβ/ET-1 animals at 21 days after surgery. Areas boxed in lower power (1.5x)
photomicrographs (a-d) are shown in higher power (10x) in panels (f-i), demonstrating
the absence of NeuN expression in the infarct. (e) Counts of neurons in the ipsilateral
striatum identified by NeuN in CQ ET-1 (n = 4) and CQ Aβ/ET-1 (n = 5) animals,
expressed as a ratio of NeuN expression in the contralateral striatum (T-test: t7 = 0.6088,
p = 0.56). Percentages indicate change from corresponding 3 day animals (T-test: CQ
ET-1, t7 = 1.907, p = 0.10; CQ Aβ/ET-1, t8 = 0.1554, p = 0.88). Values are averaged from
3 sections per brain.
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Figure 24 – Effect of Chloroquine on neuronal survival at 3 and 21 days. Detection of the
neuronal protein NeuN in the ipsilateral striatum, expressed as the ratio of contralateral
NeuN expression, at 3 (a) and 21 days (b) after surgery in untreated (white bars) and CQtreated (shaded bars) ET-1 and Aβ/ET-1 animals (3d n = 6, n = 5, n = 4, n = 5; 21d n = 6,
n = 4, n = 6, n = 5). There was no significant effect of CQ at 3 days, but there was a
significant improvement at 21 days (ANOVA: 3d, F3,16 = 1.811, p = 0.19; 21d, F3,17 =
11.42, p < 0.001, Tukey’s p < 0.05, and p < 0.01 respectively). *p < 0.05, **p < 0.01.
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significantly greater neuronal survival (87% and 79%, respectively) compared to the
corresponding untreated groups (p < 0.05 and < 0.01, respectively, Fig. 24b)
3.2.4 GM3 Expression in Chloroquine-Treated Animals
GM3 was detected at 3 days after surgery in the ipsilateral striatum of CQ-treated
animals. CQ ET-1 and CQ Aβ/ET-1 rats were not significantly different in GM3
expression volume (Fig. 25e, p > 0.05) or GM3 staining intensity (Fig. 25j, p > 0.05).
GM3 positive cells were distributed throughout the infarct region (Fig. 25g,i). CQ
treatment led to a non-significant reduction in GM3 expression volume at 3 days in CQ
ET-1 and CQ Aβ/ET-1 rats (66.4% and 61.9% of untreated OX-6 inflammation volume,
respectively) relative to the corresponding untreated groups (Fig. 27a, p > 0.05).
CQ ET-1 showed a significant decrease in GM3 expression volume from 3 to 21
days after surgery (8% of 3 day value, p < 0.05) while CQ Aβ/ET-1 showed a nonsignificant decrease from 3 to 21 days (42.6% of 3 day value, p > 0.05). At 21 days, CQ
ET-1 and CQ Aβ/ET-1 animals were not significantly different in GM3 expression
volume (Fig. 26e, p > 0.05) or staining intensity (Fig. 26j, p > 0.05). GM3 staining
appeared predominantly extracellular in the infarct core, with GM3 positive cells located
mainly around the borders of the infarct (Fig. 26g,i). CQ treatment significantly reduced
GM3 expression volume at 21 days in CQ Aβ/ET-1 animals compared to Aβ/ET-1
animals (13.1% of Aβ/ET-1, p < 0.05) and led to a non-significant reduction in CQ ET-1
animals compared to ET-1 animals (16.6% of ET-1, p > 0.05) (Fig. 27b).
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Figure 25 – GM3 expression in Chloroquine-treated animals at 3 days after surgery.
Photomicrographs of GM3 immunostaining in the ipsilateral striatum of CQ ET-1 (n = 5)
and CQ Aβ/ET-1 (n = 5) animals at 3 days after surgery. Areas boxed in lower power
(1.5x) photomicrographs (a-d) are shown in higher power (10x) in panels (f-i),
demonstrating the neuronal morphology of GM3 positive cells in the infarct. (e) GM3
expression volume and (j) GM3 staining intensity quantified throughout the ipsilateral
striatum at 3 days (T-test: Volume, t8 = 0.9375, p = 0.38; Optical Density, t8 = 0.3335, p
= 0.75)
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Figure 26 – GM3 expression in Chloroquine-treated animals at 21 days after surgery. (ad) Photomicrographs of GM3 immunostaining in the ipsilateral striatum of CQ ET-1 (n =
4) and CQ Aβ/ET-1 (n = 5) animals at 21 days after surgery. Areas boxed in lower power
(1.5x) photomicrographs (a-d) are shown in higher power (10x) in panels (f-i),
demonstrating the predominantly extracellular expression of GM3. (e) GM3 expression
volume and (j) GM3 staining intensity quantified throughout the ipsilateral striatum at 21
days (T-test: Volume, t7 = 0.8638, p = 0.42; Optical Density, t7 = 0.465, p = 0.66).
Percentages are 21 day values as a percentage of corresponding 3 day values, and *
indicates significance from 3 day CQ animals (T-test: CQ ET-1, t7 = 3.259, p < 0.05; CQ
Aβ/ET-1, t8 = 0.9986, p = 0.3472). *p < 0.05.
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Figure 27 – Effect of Chloroquine on GM3 Expression Volume at 3 and 21 days. GM3
expression volumes at 3 (a) and 21 (b) days after surgery in untreated (white bars) and
CQ-treated (shaded bars) ET-1 and Aβ/ET-1 animals (3d n = 6, n = 5, n = 4, n = 5; 21d n
= 6, n = 4, n = 6, n = 5, respectively). There was no significant effect of CQ at 3 days,
however CQ did significantly reduce GM3 expression volume at 21 days after surgery
(ANOVA: 3d F3,16 = 1.546, p = 0.24; 21d, F3,17 = 4.927, p < 0.05, Tukey’s p < 0.05). *p <
0.05.
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3.2.5 Linear Regression Analyses: Pleiotropic Effects of CQ
Linear regression analysis was performed on 21 day CQ-treated animals to
provide an estimate of the relative contribution of the pleiotropic effects of CQ on
improving neuronal survival, as both OX-6 expression volume and GM3 expression
volume showed negative correlations with enhanced neuronal survival in CQ-treated
animals. Linear regression analysis between OX-6 expression volume and neuronal
survival (%NeuN Expression) yielded an r2 of 0.89; linear regression analysis between
GM3 expression volume and neuronal survival yielded an r2 of 0.64, suggesting the antiinflammatory effects of CQ had a greater impact on improving neuronal survival than its
anti-GM3 effects.
3.2.6 GM1 and GD1b Expression in Chloroquine-Treated Animals
GM1 staining intensity was significantly reduced at 3 days after surgery in the
infarct of both CQ ET-1 (p < 0.01) and CQ Aβ/ET-1 (p < 0.05) rats compared to the
contralateral striatum (Fig. 28b,d), however they were not significantly different from one
another (Fig. 28e, p > 0.05). GM1 expression was diffuse throughout the striatum and in
the corpus callosum (Fig. 28a-d), with no obvious effects of CQ on GM1 expression. CQ
treatment improved GM1 staining intensity at 3 days, as CQ ET-1 showed a significantly
smaller deficit from the contralateral striatum than ET-1 (p < 0.05), and CQ Aβ/ET-1
showed a non-significant improvement over Aβ/ET-1 (Fig. 29a, p > 0.05).
At 21 days after surgery, GM1 staining intensity was significantly reduced in CQ
Aβ/ET-1 animals compared to the contralateral striatum (p < 0.01), while CQ ET-1 rats
showed a non-significant reduction in GM1 staining intensity in the infarct (p > 0.05).
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Figure 28 – Effect of Chloroquine on GM1 expression at 3 and 21 days in the infarct. (ad) Photomicrographs (1.5x) of GM1 immunostaining in the striatum of CQ ET-1 and CQ
Aβ/ET-1 animals at 3 and 21 (f-i) days after surgery. GM1 expression is diffuse
throughout the striatum, yet decreased in the infarct. Quantification of reduced GM1
expression in CQ ET-1 and CQ Aβ/ET-1 animals at 3 (e) and 21 (j) days after surgery (n
= 5, n = 5, n = 4, n = 5, respectively) expressed as the reduction in GM1 staining intensity
in the infarct relative to the contralateral striatum, analyzed against the expected
difference of 0 (T-test: 3d CQ ET-1, t3 = 6.709, p < 0.01; CQ Aβ/ET-1, t2 = 6.071, p <
0.05; 21d CQ ET-1, t1 = 1.832, p = 0.32; CQ Aβ/ET-1, t3 = 9.81, p < 0.01). There was no
significant difference between groups at 3 or 21 days (T-test: 3d, t5 = 0.7899, p = 0.4654;
21d, t4 = 0.8867, p = 0.43). Values are the average of 3 measurements per brain. *p <
0.05, **p < 0.01.
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Figure 29 – Effect of Chloroquine on GM1 expression at 3 and 21 days. Quantification of
reduced GM1 expression expressed as the reduction in GM1 staining intensity in the
infarct relative to the contralateral striatum at 3 (a) and 21 (b) days after surgery in
untreated (white bars) and CQ-treated (shaded bars) ET-1 and Aβ/ET-1 animals (3d n =
6, n = 5, n = 4, n = 5; 21d n = 6, n = 4, n = 6, n = 5, respectively). There was a significant
effect at 3 days, as CQ partially rescued GM1 expression in CQ ET-1 animals, however
there was no significant effect at 21 days (ANOVA: 3d, F3,11 = 6.313, p < 0.01, Tukey’s p
< 0.05; 21d, F3,8 = 2.062, p = 0.18). *p < 0.05.
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CQ ET-1 and CQ Aβ/ET-1 were not significantly different in GM1 staining intensity
(Fig. 27j, p > 0.05) and there was no significant difference from 3 to 21 days for either
group (p > 0.05). GM1 staining was diffuse throughout the striatum and present in the
corpus callosum, with no obvious effect of CQ on GM1 expression (Fig. 27f-i). CQ
treatment led to a non-significant improvement in both CQ ET-1 and CQ Aβ/ET-1
animals over the corresponding untreated groups (p > 0.05) (Fig. 29), with a modest
effect on reducing the deficit of GM1 staining intensity in the infarct.
GD1b staining intensity in the infarct was significantly reduced at 3 days after
surgery in CQ Aβ/ET-1 rats (p < 0.01), while CQ ET-1 showed a non-significant
reduction in GD1b staining intensity in the infarct compared to the contralateral striatum.
There was no significant difference between CQ ET-1 and CQ Aβ/ET-1 rats in GD1b
staining intensity (Fig. 30e, p > 0.05). CQ treatment had no observable effect on GD1b
expression at 3 days after surgery (Fig. 30a-d), and had no significant effect compared to
untreated groups, as there were no significant differences across all groups 3 days (Fig.
31a, p > 0.05).
At 21 days after surgery, GD1b staining intensity in the infarct was significantly
reduced relative to the contralateral striatum in CQ Aβ/ET-1 animals (p < 0.01), but not
in CQ ET-1 animals (p > 0.05). CQ ET-1 and CQ Aβ/ET-1 rats were not significantly
different from one another at 21 days in GD1b staining intensity (Fig. 30j, p > 0.05).
There was no significant difference between 3 and 21 days in GD1b staining intensity for
CQ ET-1 and CQ Aβ/ET-1 rats (p > 0.05). CQ treatment led to a non-significant
improvement in CQ ET-1 over ET-1, partially reducing the deficit in GD1b staining
intensity in the infarct (Fig. 31b, p > 0.05).
	
  93	
  

	
  

	
  

	
  

	
  

Figure 30 – Effect of Chloroquine on GD1b expression at 3 and 21 days in the infarct. (ad) Photomicrographs (1.5x) of GD1b immunostaining in the striatum of CQ ET-1 and CQ
Aβ/ET-1 animals at 3 and 21 (f-i) days after surgery. GD1b expression is diffuse
throughout the striatum, yet decreased in the infarct. Quantification of reduced GD1b
expression in CQ ET-1 and CQ Aβ/ET-1 animals at 3 (e) and 21 (j) days after surgery (n
= 5, n = 5, n = 4, n = 5, respectively) expressed as the reduction in GD1b staining
intensity in the infarct relative to the contralateral striatum, analyzed against the expected
difference of 0 (T-test: 3d CQ ET-1, t3 = 2.776, p = 0.7; CQ Aβ/ET-1, t2 = 15.33, p <
0.01; 21d CQ ET-1, t3 = 5.44, p = 0.12; CQ Aβ/ET-1, t4 = 5.903, p < 0.01). There was no
significant difference between groups at 3 or 21 days (T-test: 3d, t5 = 0.5253, p = 0.62;
21d, t4 = 1.369, p = 0.24).
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Figure 31 – Effect of Chloroquine on GD1b expression at 3 and 21 days. Quantification
of reduced GD1b expression in the infarct expressed as the reduction in GD1b staining
intensity relative to the contralateral striatum at 3 (a) and 21 (b) days after surgery in
untreated (white bars) and CQ-treated (shaded bars) ET-1 and Aβ/ET-1 animals (3d n =
6, n = 5, n = 4, n = 5; 21d n = 6, n = 4, n = 6, n = 5, respectively). There was no
significant effect of CQ at 3 or 21 days (ANOVA: 3d, F3,11 = 0.38, p = 0.7664; 21d, F3,8 =
3.397, p = 0.07).
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Section 4
DISCUSSION
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In line with our previous findings demonstrating synergistic pathology in a co-

morbid animal model of stroke and Aβ toxicity (Whitehead et al., 2005a, 2005b, 2007),
this is the first study to demonstrate that Aβ toxicity can aggravate stroke-induced
pathogenic changes in ganglioside expression. This supports our initial hypothesis and
confirms that 1) GM3 is detectable in our unilaterial ET-1 induced striatal stroke model
and is associated with reduced expression of complex gangliosides, neuroinflammation
and neuronal loss; and 2) GM3 expression is synergistically enhanced in our combined
model at 21 days after ischemia, colocalizing in neurons and degenerating cells
suggesting that GM3 accumulation is a synergistic pathway mediating the combined
pathological effects of stroke and Aβ toxicity.
CQ was also tested as a proof of principle approach in preventing the pathogical
changes in ganglioside expression, and we are the first to show that CQ can effectively
limit GM3 expression and inflammation 21 days following stroke. This supports our
hypothesis and confirms that 3) CQ reduced the expression of GM3 and reduced neuronal
loss after ischemia. A proposed pathway demonstrating the interaction between stroke
and Aβ toxicity and the pleiotropic effects of Chloroquine is shown in Fig. 32.
4.1 Neuroinflammation
Neuroinflammation is intimately associated with both stroke and AD
(Ekelenboom et al., 1994; Yamashima and Oikawa, 2009), and previous efforts by our
lab and others implicate inflammation as the primary pathway mediating the combined
pathogenic effects when stroke and Aβ toxicity are combined (Zhang et al., 1997;
Whitehead et al., 2005a; 2007a; Koistinaho et al., 2002) (Fig. 32). As a key component to
the inflammatory response (Bruce-Keller, 1999; Marks et al., 2001), ramified
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Figure 32 – Proposed mechanism of Chloroquine. Chloroquine demonstrates pleiotropic
effects in improving neuronal survival in a co-morbid model of stroke and Aβ toxicity.
Boxes highlighted in blue were demonstrated in this study.
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microglia were readily detected by increased expression of OX-6 and taken as a correlate
of neuroinflammation. Aβ had no effect on OX-6 expression in the striatum at 21 days
after surgery, however the striatum isn’t an area that has shown to be affected by this
model of generalized Aβ toxicity (Whitehead et al., 2005a; Cheng et al., 2006). Aβ/ET-1
rats showed no effect of Aβ at 3 days on OX-6 expression compared to ET-1 rats,
however Aβ-mediated effects are not expected to be acute (Jack et al, 2010). After 21
days, both ET-1 and Aβ/ET-1 rats showed significant increases in OX-6 expression
volume from 3 days, suggesting that the neuroinflammatory response was still active. Aβ
toxicity had a non-additive effect on increasing OX-6 expression volume at 21 days,
suggesting potentiation of the inflammatory response as reported in other co-morbid
models of stroke and AD (Zhang et al., 1997; Sheng et al., 2003; Koistinaho et al., 2002).
In the presence of Aβ toxicity there was significant progressive growth of the
infarct, as also reported by Whitehead et al. (2007a). Unlike Whitehead et al. (2007a)
however, ET-1 also showed a progressive increase (though not as large as Aβ/ET-1) and
we did not see a significant difference in OX-6 expression volume between ET-1 and
Aβ/ET-1 over time. This discrepancy is likely a result of using a greater concentration of
ET-1 (60 pmol vs 6 pmol) and thus a larger initial injury, revealing a potential ceiling
effect of Aβ toxicity in enhancing the inflammatory response. Physical barriers - such as
the corpus callosum and lateral ventricle – likely restrict the spread of the uninhibited
growth of the infarct in the striatum, which may also limit the observable effects of the
combination of Aβ toxicity and stroke.
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CQ treatment had no effect on reducing OX-6 expression at 3 days, however it

reduced OX-6 expression volume in both CQ ET-1 (29.9% of ET-1) and CQ Aβ/ET-1
(22.1% of Aβ/ET-1) rats after 21 days by reducing the progressive increase in OX-6
expression volume. The primary injury is largely irreversible following ischemia
(Obrenovitch, 1995) however limiting the secondary neuronal loss may be an effective
strategy for therapeutic intervention.
4.2 GM3 Expression
GM3 was not detected in Aβ or Reverse rats at 21 days after surgery. Kruetz et al.
(2011) showed that hippocampal slices incubated with pre-aggregated Aβ25-35 increased
GM3 expression concomitantly with cell death, while soluble Aβ25-35 had no effect on
GM3 expression. However others have reported that soluble Aβ is more neurotoxic than
the insoluble Aβ fibrils found in amyloid plaques (Benilova et al., 2012), highlighting the
need for consensus on the most accurate way to model Aβ toxicity. Kracun et al. (1991)
demonstrated that GM3 accumulated in regions of neurodegeneration in AD brains, and
hypothesized that it was due to the accelerated lysosomal breakdown of complex
gangliosides. It was later shown in an ex vivo model of AD that AD patients show
enhanced β-galactosidase activity (Emiliani et al., 2003) – which is responsible for
degradation of complex gangliosides into GM3 – and that β-galactosidase activity
correlated with the severity of dementia (Pitto et al., 2004). The accumulation of GM3
was also found to correlate with CAA (Oikawa et al., 2009; Yu et al., 2012), however it is
not clear whether GM3 accumulation occurs early or after the onset of AD pathogenesis.
Glutamate toxicity is the primary mechanism responsible for the propagation of
stroke damage (Simon et al., 1984), leading to generation of ROS which cause oxidative
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stress and massive cell death (Yamashima and Oikawa, 2009). In the present experiment,
the confirmation of GM3 expression in our model of striatal infarct lends further support
that GM3 is a viable therapeutic target for ischemic stroke, as increased GM3 levels have
been shown to mediate the generation of ROS following glutamate toxicity (Sohn et al.,
2006) and GM3 expression had previously only been demonstrated in MCAO models of
stroke (Kwak et al., 2005; Whitehead et al., 2011). Aβ toxicity had no effect on ET-1
induced expression of GM3 at 3 days, however the combination of stroke and Aβ toxicity
resulted in a synergistic increase in GM3 expression at 21 days in Aβ/ET-1 rats. To our
knowledge this is the first study to demonstrate that the stroke-induced accumulation of
GM3 can be potentiated by Aβ toxicity.
In agreement with Marconi et al. (2005), GFAP-positive astrocytes did not colocalize with GM3, however GM3 did co-localize with IbA-1 positive macrophages:
Marconi et al. (2005) found microglia were not positive for GM3 in the human CNS, yet
also stated that ganglioside expression studies often show conflicting results between
models. GM3 is expressed by peripheral monocytes (Kiguchi et al., 1990) and is believed
to control their differentiation into resident macrophages, as observed in atherosclerotic
lesions (Gracheva et al., 2009) where there is high inflammatory involvement. The
relationship between GM3 expression and TNFα – an inflammatory cytokine - is far from
clear (Prokazova et al., 2009; Inokuchi, 2011) but GM3 may itself by an inflammatory
signal by controlling macrophage differentiation, or indirectly by regulating TNFα
expression.
The two previous studies to detect GM3 following stroke proposed very different
explanations on the role of GM3 in the infarct: Kwak et al. (2005) suggested that GM3
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accumulation is a neuroprotective response indicating increased ganglioside biosynthesis,
while Whitehead et al. (2011) proposed that GM3 plays a role in the expansion of the
infarct over time. The majority of GM3 positive cells exhibited a neuronal morphology,
which was confirmed by immunofluorescence and co-localization of GM3 with NeuN.
The cellular expression pattern of GM3 appeared to propagate from the core of the infarct
into the periphery from 3 to 21 days, suggesting expansion of the infarct into the
surrounding penumbra in support of Whitehead et al. (2011). At 21 days after surgery
GM3 positive cells were largely absent within the necrotic core, where the expression
pattern of GM3 was largely extracellular. Gangliosides can be shed from neuronal
membranes as the result of normal membrane turnover (Malisan and Testi, 2002), and
during degenerative processes there is increased membrane turnover (Miyatani et al.,
1990; Trbojevic-Cepe et al., 1991; Tarvonen-Schroder et al., 1997; Andersson et al.,
1998). The role of non-cell associated gangliosides is not yet clear (Malisan and Testi,
2002), however increased GM3 levels in the CSF are indicative of BBB dysfunction or
cerebral hemorrhage (Trbojevic-Cepe et al., 1991), as GM3 is the major serum
ganglioside (Lopez and Schnaar, 2009).
Having shown a drastic increase in GM3 expression levels, we investigated the
expression of complex gangliosides in order to characterize their expression in the infarct
in relation to the accumulation of GM3. Our results suggest that expression of complex
gangliosides is reduced in the infarct at 3 and 21 days. Despite a drastic increase in GM3
that was potentiated by Aβ, our results only showed a modest reduction in GM1 and
GD1b expression that was not significantly enhanced in the presence of Aβ toxicity. It is
well-established that ganglioside levels are reduced following stroke (Rastogi et al., 1968;
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Domanska-Janik et al., 1982; Qi and Xue, 1991; Ramirez et al., 2003), however we were
limited by our experimental design and could not quantify total ganglioside content nor
compare between ganglioside species by immunohistochemistry. These results do still
provide support to the hypothesis that GM3 accumulation in the infarct is the result of the
degradation of complex gangliosides and not increased ganglioside biosynthesis.
Interestingly, at 21 days both GM1 and GD1b appeared concentrated around the border
of the infarcted tissue similar to the results of Whitehead et al. (2011), who theorized that
this up-regulation may be an effort to potentiate neurotrophic effects in neighbouring
tissue. In support of this idea, Marconi et al. (2005) showed that astrocytes – which
function to support neuronal survival (Akasako et al., 2011) – co-express GM1 and
GD1b. We did not however determine the cellular expression patterns of GM1 and GD1b
via immunofluorescence to further support this hypothesis.
Due to its lysomotropic properties, CQ has been used in vitro to inhibit the
degradation of complex gangliosides to GM3 (Riboni et al., 1991,1995), however this is
the first study to demonstrate that CQ is effective in vivo as a novel therapeutic in
preventing the accumulation of GM3 following stroke. At 3 days, CQ reduced GM3
expression volume by 34% and 38% in CQ ET-1 and CQ Aβ/ET-1 animals, respectively,
compared to the corresponding untreated animals. By 21 days, CQ treatment reduced
GM3 expression volume to 13% and 16%, respectively, of the corresponding untreated
animals. However, CQ had less of an effect on preserving the expression of complex
gangliosides, as CQ only showed a slight improvement that reduced the deficit in staining
intensity between the infarct and the contralateral striatum. This is likely due to the
limitations inherent in the analysis of the immunostaining, which was measured as a ratio
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of staining intensity in the infarct compared to the contralateral striatum: CQ can’t
increase expression above 100% of the contralateral striatum by preventing degradation,
as it is also acting upon the contralateral striatum. Future studies with CQ that test the
total ganglioside content could provide important evidence supporting further testing with
CQ as a therapeutic for stroke.
4.3 Neurodegeneration
Ischemia triggers both apoptotic and necrotic cell death and results in massive
cellular loss (Gabryel et al., 2012), which is enhanced in the presence of Aβ-toxicity
(Whitehead et al., 2005a; 2007a; Zhang et al., 1997; Koistinaho et al., 2002).
Neurodegeneration was assessed with FJB, a marker of cellular degeneration nonspecific
for cell type or type of cell death (Schmued and Hopkins, 2000; Damjanac et al., 2006)
and NeuN, a neuronal protein marker, as complementary approaches: FJB positive cells
were counted in the ipsilateral striatum, while NeuN expressing cells in the ipsilateral
striatum were counted and expressed as a ratio of NeuN expressing cells in the
contralateral striatum.
At 3 days there was extensive neurodegeneration in the ipsilateral striatum, with
ET-1 and Aβ/ET-1 losing 35% and 40% of NeuN-expressing cells, and FJB positive cells
distributed extensively throughout the infarct. Aβ toxicity had no effect on
neurodegeneration at 3 days, though it has been reported to increase neuronal
susceptibility to excitotoxic damage (Koh, Yang and Cotman, 1990). It is worthwhile to
note that during surgery, Aβ toxicity was induced immediately prior to the ischemic
striatal infarct, and Aβ effects are not expected to be acute (Jack et al., 2010), while other
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reports were performed in transgenic AD mice, which are exposed to elevated
concentrations of Aβ from birth (Zhang et al., 1997; Koistinaho et al., 2002). Regardless,
the progressive neuronal loss following stroke from 3 to 21 days was greater in the
presence of Aβ toxicity, as Aβ/ET-1 rats demonstrated ongoing cellular degeneration at
21 days, as well as significantly greater neuronal loss by 21 days compared to ET-1 rats
(42% in ET-1 rats and 58% in Aβ/ET-1 rats). At 21 days, the necrotic core of the infarct
was void of FJB-positive and NeuN-expressing cells, with FJB positive cells located
around the periphery of the infarct showing a similar pattern of propagation as GM3positive cells. FJB co-localized with GM3 cells by immunofluorescence, suggesting that
GM3 accumulation is involved in the expansion of the infarct into the penumbra
(Whitehead et al., 2011).
The results of the FJB and NeuN quantification were complementary, though not
identical, and there are several explanations for this discrepancy. First, the two markers
were quantified differently in order to allow for appropriate analyses. Second, there is the
possibility that neurons may reduce NeuN expression without subsequently dying; and
third, that unlike NeuN, FJB is not a cell-specific marker and has shown to pick up
degenerating microglia and astrocytes as well as neurons (Damjanac, 2006).
CQ treatment was unable to prevent the acute neurodegeneration at 3 days even
with 3 days of pretreatment, however it attenuated the progressive neurodegeneration
from 3 to 21 days, effectively inhibiting growth of the infarct resulting in significantly
improved neuronal survival at 21 days in both CQ ET-1 and CQ Aβ/ET-1 rats compared
to the corresponding untreated groups (28% and 34% improvement, respectively). CQ
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Aβ/ET-1 rats showed no effect of Aβ toxicity at 3 days, however in the presence of Aβ
stroke resulted in greater ongoing cellular degeneration from 3 to 21 days.
Linear regression analyses suggests that CQ had its greatest effect on improving
neuronal survival at 21 days with its anti-inflammatory effect, specifically in reducing
OX-6 expression volume. However, the correlation between reduced GM3 expression
volume and improved neuronal survival suggests that the reduction in GM3 also had an
effect on improving neuronal survival. Together, these results suggest that inflammation
is the primary mechanism underlying the interaction between stroke and Aβ toxicity, and
that along with GM3 accumulation both contribute to neurodegeneration.
4.4 Limitations
There are some limitations to this study, however they are likely to be resolved by
future experiments. The major limitation to this study is that CQ-treated animals were not
generated simultaneously with untreated animals in an effort to reduce the number of
animals used. However, all animals were randomly assigned to their experimental groups
and the same individual performed all CQ injections and surgeries to ensure consistency.
This experiment was a proof-of-principle study to determine if CQ was able to augment
GM3 expression, and CQ was administered in a pre-treatment paradigm. As this is the
first study to use CQ as a therapeutic for stroke, the treatment regimen may not have been
optimal and therefore generated a less robust outcome. CQ warrants future investigations,
however they must be carried out at various dosages as randomized control studies in
order to determine the clinical viability of CQ.
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Another limitation of the present study is that histological benefit can occur in the

absence of a functional benefit following stroke (Hiltunen et al., 2009). It is important to
demonstrate a functional impairment in our stroke model (i.e. adhesive removal test, grip
strength) and test if CQ treatment provides a functional improvement as well as a
histological improvement in future studies.
4.5 Future studies
The identification of GM3 accumulation as a point of synergism between stroke
and Aβ toxicity (Fig. 32) and its potential role in expansion of the infarct (Whitehead et
al., 2011) may provide mechanistic insight into the bidirectional relationship between
stroke and Aβ toxicity. In line with the ex vivo work of Pitto et al. (2004) in which GM3
levels were correlated with the degree of cognitive impairment in AD patients, our work
correlated GM3 expression with neuronal loss following stroke. Sohn et al. (2006)
concluded that therapeutic strategies for neurodegenerative disorders should be focused
on controlling GM3 levels, however few viable or effective strategies have been tested.
The present study supports the theory that GM3 accumulation is the result of the
degradation of complex gangliosides (Kracun et al., 1991). This is the first study to
selectively prevent the accumulation of GM3 without depleting all other ganglioside
species (Sohn et al., 2006; Akasako et al., 2011). CQ provides a novel therapeutic
approach in managing GM3, while also displaying anti-inflammatory properties, and
warrants future investigation to delineate these effects. Future studies with CQ can be
carried out to determine if CQ also improves neuronal survival by acting via sigma-1
receptors (Hirata et al., 2011) or via inhibition of autophagy, which have both proven
beneficial following stroke (Zhang et al., 2010, 2011).
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To improve our understanding of the regulation of ganglioside expression

following stroke and the effects of CQ on complex ganglioside expression, future studies
by our lab will employ MALDI mass spectrometry imaging. MALDI imaging allows for
the simultaneous imaging of all major ganglioside species in situ and the semiquantitative analysis of ganglioside levels (Chan et al., 2009; Sugiura et al., 2008;
Whitehead et al., 2011), circumventing any issues with immunohistochemistry targeted
towards gangliosides.
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Section 5
SUMMARY AND CONCLUSIONS
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Summary of Key Findings
1. Aβ and Reverse animals showed no inflammation, neurodegeneration or GM3
expression in the striatum at 21 days.
2. ET-1 and Aβ/ET-1 groups showed no significant differences at 3 days.
3. Aβ/ET-1 showed significantly greater neuronal loss and GM3 expression volume
than ET-1 at 21 days.
4. GM1 and GD1b expression was significantly reduced in the infarct at 3 and 21
days.
5. Immunofluorescence indicated co-localization of GM3 with NeuN, FJB and IbA1.
6. CQ treatment had no significant effect at 3 days.
7. CQ treatment significantly improved neuronal survival, reduced OX-6 expression
volume and GM3 expression volume at 21 days, and partially reduced the deficit
of complex ganglioside expression in the infarct.
8. Simple linear regression with neuronal survival at 21 days indicated an r2 of 0.89
for OX-6 expression volume, and 0.64 for GM3 expression volume.
Conclusions
The combination of stroke and Aβ toxicity led to synergistic inflammation and
pathological ganglioside expression, resulting in significant neuronal loss in the Wistar
rat. Chloroquine treatment for 7 days, beginning 3 days prior to ischemia, improved
neuronal survival and reduced inflammation and accumulation of GM3, suggesting it
may have improved outcomes by limiting the neurotoxic effects of inflammation and by

110	
  
	
  

	
  

	
  

	
  

	
  

preventing the degradation of complex gangliosides. Together, these findings suggest that
stroke and Aβ toxicity pathways converge upon the neuroinflammatory cascade as well
as the pathological accumulation of GM3, and that Chloroquine holds promise as a novel
treatment to improve neuronal survival following stroke.
This study provides critical support for the identification of GM3 as a point of
synergism between stroke and Aβ toxicity, as well as a potential mechanism for
preventing the accumulation of GM3 while maintaining expression of complex
gangliosides which are critical for neuronal functioning and repair. Aberrant GM3
expression has been implicated in stroke (Kwak et al., 2005; Sohn et al., 2006; Whitehead
et al., 2011), diabetes mellitus (Inokuchi, 2011), atherosclerosis (Gracheva et al., 2009),
LDL cholesterol levels (Inokuchi, 2011) and AD (Kracun et al., 1991; Pitto et al., 2004;
Yanagisawa et al., 1995) and thus may represent a point of overlap between multiple risk
factors for AD and AD itself, making it a potentially ideal biomarker as well as an
effective therapeutic target.
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